

Substitute for form 1449A&B/PTO				Complete if Known Application Number 10/621,254 Filing Date July 14, 2003 First Named Inventor Dow, Steven W. Art Unit 1643 Examiner Name HOLLERAN, Anne L. Attorney Docket Number 021819-000300US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	1	of	48		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US-3,906,092	9/1975	Hilleman, et al.	
	AB	US-4,452,775	06/05/1984	Kent	
	AC	US-4,956,296	9/1990	Fahnestock	
	AD	US-4,981,684	01/01/1991	MacKenzie, et al.	
	AE	US-5,023,243	06/11/1991	Tullis	
	AF	US-5,075,109	12/24/1991	Tice, et al.	
	AG	US-5,087,617	02/11/1992	Smith	
	AH	US-5,178,880	01/12/1993	MacKenzie, et al.	
	AI	US-5,234,811	8/1993	Beutler, et al.	
	AJ	US-5,248,670	09/28/1993	Draper, et al.	
	AK	US-5,457,189	10/10/1995	Crooke, et al.	
	AL	US-5,514,577	05/07/1996	Draper, et al.	
	AM	US-5,543,152	08/06/1996	Webb, et al.	
	AN	US-5,663,153	9/1997	Hutcherson, et al.	
	AO	US-5,567,604	10/22/1996	Rando, et al.	
	AP	US-5,576,302	11/19/1996	Cook, et al.	
	AQ	US-5,585,479	12/1996	Hoke, et al.	
	AR	US-5,594,122	01/14/1997	Friesen	
	AS	US-5,595,758	01/21/1997	Baily, et al.	
	AT	US-5,658,891	08/19/1997	Draper, et al.	
	AU	US-5,665,580	09/09/1997	Crooke, et al.	
	AV	US-5,679,354	10/21/1997	Morein, et al.	
	AW	US-5,681,944	10/28/1997	Crooke, et al.	
	AX	US-5,723,335	3/1998	Hutcherson, et al.	
	AY	US-5,736,152	04/07/1998	Dunn	
	AZ	US-5,753,613	05/19/1998	Ansell, et al.	
	BA	US-5,756,097	05/26/1998	Landucci, et al.	
	BB	US-5,766,920	06/16/1998	Babbitt, et al.	
	BC	US-5,780,448	07/14/1998	Davis	
	BD	US-5,785,992	07/28/1998	Ansell, et al.	
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
				Dow, Steven W.	
				Art Unit	
				1643	
				Examiner Name	
				HOLLERAN, Anne L.	
				Attorney Docket Number	
				021819-000300US	
Sheet	2	of	48		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	BE	US-5,786,189	7/1998	Locht, et al.	
	BF	US-5,804,566	09/08/1998	Carson, et al.	
	BG	US-5,814,335	09/29/1998	Webb, et al.	
	BH	US-5,837,243	11/17/1998	Deo, et al.	
	BI	US-5,843,770	12/01/1998	Ill, et al.	
	BJ	US-5,849,719	12/1998	Carson, et al.	
	BK	US-5,854,418	12/29/1998	Chang, et al.	
	BL	US-5,858,987	01/12/1999	Beer-Romero, et al.	
	BM	US-5,877,309	03/02/1999	McKay, et al.	
	BN	US-5,955,059	09/21/1999	Gilchrest, et al.	
	BO	US-5,965,542	10/12/1999	Wassan, et al.	
	BP	US-5,968,909	10/19/1999	Agrawal, et al.	
	BQ	US-5,985,662	11/16/1999	Anderson, et al.	
	BR	US-5,997,858	12/07/1999	Tovey, et al.	
	BS	US-6,027,726	02/22/2000	Ansell	
	BT	US-6,027,732	02/22/2000	Morein, et al.	
	BU	US-6,030,954	02/29/2000	Wu, et al.	
	BV	US-6,030,955	02/29/2000	Stein, et al.	
	BW	US-6,090,791	07/18/2000	Sato, et al.	
	BX	US-6,107,062	08/22/2000	Hu, et al.	
	BY	US-6,110,745	08/29/2000	Zhang, et al.	
	BZ	US-6,114,167	09/05/2000	Symonds, et al.	
	CA	US-6,121,434	09/19/2000	Peyman, et al.	
	CB	US-6,184,369 B1	02/06/2001	Rando, et al.	
	CC	US-6,207,819 B1	03/27/2001	Manoharan, et al.	
	CD	US-6,214,806 B1	04/10/2001	Krieg, et al.	
	CE	US-6,218,371 B1	04/17/2001	Krieg, et al.	
	CF	US-6,221,882 B1	04/24/2001	Macfarlane	
	CG	US-6,239,116 B1	05/29/2001	Krieg, et al.	
	CH	US-6,348,312	02/19/2002	Peyman, et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/621,254
		Filing Date	July 14, 2003
		First Named Inventor	Dow, Steven W.
		Art Unit	1643
		Examiner Name	HOLLERAN, Anne L.
<i>(Use as many sheets as necessary)</i>		Attorney Docket Number	021819-000300US
Sheet	3	of	48

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	CI	US-6,399,630	06/04/2002	Macfarlane	
	CJ	US-6,426,334 B1	07/30/2002	Agrawal, et al.	
	CK	US-6,429,199 B1	08/06/2002	Krieg, et al.	
	CL	US-6,476,000 B1	11/05/2002	Agrawal, et al.	
	CM	US-6,479,504	11/12/2002	Macfarlane, et al.	
	CN	US-6,521,637	02/18/2003	Macfarlane	
	CO	US-6,544,518 B1	04/08/2003	Friede, et al.	
	CP	US-6,558,670 B1	05/06/2003	Friede, et al.	
	CQ	US-6,605,708	08/12/2003	Habus, et al.	
	CR	US-6,610,308	08/26/2003	Haensler	
	CS	US-6,610,661 B1	08/26/2003	Carson, et al.	
	CT	US-6,620,805	09/16/2003	Takle, et al.	
	CU	US-6,653,292 B1	11/25/2003	Krieg, et al.	
	CV	US-6,630,455 B1	10/07/2003	Mitchell	
	CW	US-6,727,230 B1	04/27/2004	Hutcherson, et al.	
	CX	US-6,815,429 B2	11/09/2004	Agrawal	
	CY	US-6,821,957 B1	11/23/2004	Krieg, et al.	
	CZ	US-6,835,395 B1	12/28/2004	Simple, et al.	
	DA	US-6,849,725 B2	02/01/2005	Junghans, et al.	
	DB	US-6,943,240	09/13/2005	Bauer, et al.	
	DC	US-6,949,520	09/27/2005	Hartmann, et al.	
	DD	US-7,001,890	02/28/2006	Wagner, et al.	
	DE	US-7,105,495 B2	09/12/2006	Agrawal, et al.	
	DF	US-7,192,222 B2	10/31/2006	Van Nest, et al.	
	DG	US-2001/0036462 A1	11/01/2001	Fong, et al.	
	DH	US-2002/0009457 A1	01/24/2002	Bowerstock, et al.	
	DI	US-2002/0055477 A1	05/09/2002	Van Nest, et al.	
	DJ	US-2002/0065236 A1	05/30/2002	Yew, et al.	
	DK	US-2002/0091097 A1	07/11/2002	Bratzler, et al.	
	DL	US-2002/0137714 A1	09/25/2002	Kandamilla, et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/621,254
		Filing Date	July 14, 2003
		First Named Inventor	Dow, Steven W.
		Art Unit	1643
		Examiner Name	HOLLERAN, Anne L.
Sheet	4	of	48
		Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number <small>Number Kind Code² (if known)</small>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	DM	US-2002/0164341 A1	11/07/2002	Davis, et al.	
	DN	US-2002/0192184 A1	12/19/2002	Carpentier, et al.	
	DO	US-2003/0022852 A1	01/30/2003	Van Nest, et al.	
	DP	US-2003/0022854 A1	01/30/2003	Dow, et al.	
	DQ	US-2003/0026801 A1	02/06/2003	Weiner, et al.	
	DR	US-2003/0050261 A1	03/13/2003	Krieg, et al.	
	DS	US-2003/0050268 A1	03/13/2003	Krieg, et al.	
	DT	US-2003/0059773 A1	03/27/2003	Van Nest, et al.	
	DU	US-2003/0086900 A1	05/08/2003	Low, et al.	
	DV	US-2003/0091599 A1	05/15/2003	Davis, et al.	
	DW	US-2003/0100527 A1	05/29/2003	Krieg, et al.	
	DX	US-2003/0104044 A1	06/05/2003	Semple, et al.	
	DY	US-2003/0109469 A1	06/12/2003	Carson, et al.	
	DZ	US-2003/0119774 A1	06/26/2003	Foldvari, et al.	
	EA	US-2003/0125279 A1	07/03/2003	Junghans, et al.	
	EB	US-2003/0129251 A1	07/10/2003	Van Nest, et al.	
	EC	US-2003/0139364 A1	07/24/2003	Krieg, et al.	
	ED	US-2003/0148316 A1	08/07/2003	Lipford, et al.	
	EE	US-2003/0148976 A1	08/07/2003	Krieg, et al.	
	EF	US-2003/0165478 A1	09/04/2003	Sokoll, et al.	
	EG	US-2003/0181406 A1	09/25/2003	Schetter, et al.	
	EH	US-2003/0186921 A1	10/02/2003	Carson, et al.	
	EI	US-2003/0191079 A1	10/09/2003	Krieg, et al.	
	EJ	US-2003/0203861 A1	10/30/2003	Carson, et al.	
	EK	US-2003/0212026 A1	11/13/2003	Krieg, et al.	
	EL	US-2003/0224010 A1	12/04/2003	Davis, et al.	
	EM	US-2003/0232074 A1	12/18/2003	Lipford, et al.	
	EN	US-2003/0232780 A1	12/18/2003	Carson, et al.	
	EO	US-2003/0232856 A1	12/18/2003	Macfarlane	
	EP	US-2004/0006010 A1	01/08/2004	Carson, et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
				Art Unit	
				1643	
				Examiner Name	
				HOLLERAN, Anne L.	
				Attorney Docket Number	
				021819-000300US	
Sheet	5	of	48		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Doc No.	Document Number Number Kind Code ^(if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	EQ	US-2004/0006034 A1	01/08/2004	Raz, et al.	
	ER	US-2004/0009949 A1	01/15/2004	Krieg	
	ES	US-2004/0013688 A1	01/22/2004	Wise, et al.	
	ET	US-2004/0030118 A1	02/12/2004	Wagner, et al.	
	EU	US-2004/0038922 A1	02/26/2004	Haensler, et al.	
	EV	US-2004/0047869 A1	03/11/2004	Garcon, et al.	
	EW	US-2004/0053880 A1	03/18/2004	Krieg, et al.	
	EX	US-2004/0058883 A1	03/25/2004	Phillips, et al.	
	EY	US-2004/0067902 A9	04/08/2004	Bratzler, et al.	
	EZ	US-2004/0067905 A1	04/08/2004	Krieg, et al.	
	FA	US-2004/0087534 A1	05/06/2004	Krieg, et al.	
	FB	US-2004/0087538 A1	05/06/2004	Krieg, et al.	
	FC	US-2004/0092468 A1	05/13/2004	Schwartz, et al.	
	FD	US-2004/0092472 A1	05/13/2004	Krieg, et al.	
	FE	US-2004/0097719 A1	05/20/2004	Agrawal, et al.	
	FF	US-2004/0106568 A1	06/03/2004	Krieg, et al.	
	FG	US-2004/0131628 A1	07/08/2004	Bratzler, et al.	
	FH	US-2004/0132677 A1	07/08/2004	Fearon, et al.	
	FI	US-2004/0132685 A1	07/08/2004	Krieg, et al.	
	FJ	US-2004/0136948 A1	07/15/2004	Fearon, et al.	
	FK	US-2004/0142469 A1	07/22/2004	Krieg, et al.	
	FL	US-2004/0143112 A1	07/22/2004	Krieg, et al.	
	FM	US-2004/0143112 A1	07/22/2004	Krieg, et al.	
	FN	US-2004/0147468 A1	07/29/2004	Krieg, et al.	
	FO	US-2004/0152649 A1	08/05/2004	Krieg, et al.	
	FP	US-2004/0152656 A1	08/05/2004	Krieg, et al.	
	FQ	US-2004/0152657 A1	08/05/2004	Krieg, et al.	
	FR	US-2004/0157791 A1	08/12/2004	Dow, et al.	
	FS	US-2004/0162258 A1	08/19/2004	Krieg, et al.	
	FT	US-2004/0162262 A1	08/19/2004	Krieg, et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[†] Applicant's unique citation designation number (optional). ^{*} Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
				Examiner Name	HOLLERAN, Anne L.
Sheet	6	of	48	Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	FU	US-2004/0167089 A1	08/26/2004	Krieg, et al.	
	FV	US-2004/0171150 A1	09/02/2004	Krieg, et al.	
	FW	US-2004/0171571 A1	09/02/2004	Krieg, et al.	
	FX	US-2004/0181045 A1	09/16/2004	Krieg, et al.	
	FY	US-2004/0198680 A1	10/07/2004	Krieg	
	FZ	US-2004/0198688 A1	10/07/2004	Krieg, et al.	
	GA	US-2004/0229835 A1	11/18/2004	Krieg, et al.	
	GB	US-2004/0234512 A1	11/25/2004	Wagner, et al.	
	GC	US-2004/0235770 A1	11/25/2004	Davis, et al.	
	GD	US-2004/0235774 A1	11/25/2004	Davis, et al.	
	GE	US-2004/0235777 A1	11/25/2004	Wagner, et al.	
	GF	US-2004/0235778 A1	11/25/2004	Wagner, et al.	
	GG	US-2004/0248837 A1	12/09/2004	Raz, et al.	
	GH	US-2004/0266719 A1	12/30/2004	McCluskie, et al.	
	GI	US-2005/0004061 A1	01/06/2005	Krieg, et al.	
	GJ	US-2005/0004062 A1	01/06/2005	Krieg, et al.	
	GK	US-2005/0004144 A1	01/06/2005	Carson, et al.	
	GL	US-2005/0009774 A1	01/13/2005	Krieg, et al.	
	GM	US-2005/0013812 A1	01/20/2005	Dow, et al.	
	GN	US-2005/0031638 A1	02/10/2005	Dalemans, et al.	
	GO	US-2005/0032734 A1	02/10/2005	Davis, et al.	
	GP	US-2005/0032736 A1	02/10/2005	Krieg, et al.	
	GQ	US-2005/0037403 A1	02/17/2005	Krieg, et al.	
	GR	US-2005/0037985 A1	02/17/2005	Krieg, et al.	
	GS	US-2005/0043529 A1	02/24/2005	Davis, et al.	
	GT	US-2005/0049215 A1	03/03/2005	Krieg, et al.	
	GU	US-2005/0049216 A1	03/03/2005	Krieg, et al.	
	GV	US-2005/0054601 A1	03/10/2005	Wagner, et al.	
	GW	US-2005/0054602 A1	03/10/2005	Krieg, et al.	
	GX	US-2005/0059619 A1	03/17/2005	Krieg, et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/621,254	
			Filing Date	July 14, 2003	
			First Named Inventor	Dow, Steven W.	
			Art Unit	1643	
			Examiner Name	HOLLERAN, Anne L.	
Sheet	7	of	48	Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	GY	US-2005/0059625 A1	03/17/2005	Krieg, et al.	
	GZ	US-2005/0064401 A1	03/24/2005	Olek, et al.	
	HA	US-2005/0070491 A1	03/31/2005	Krieg, et al.	
	HB	US-2005/0075302 A1	04/07/2005	Hutcherson, et al.	
	HC	US-2005/0079152 A1	04/14/2005	Bot, et al.	
	HD	US-2005/0100983 A1	05/12/2005	Bauer, et al.	
	HE	US-2005/0101554 A1	05/12/2005	Krieg, et al.	
	HF	US-2005/0101557 A1	05/12/2005	Krieg, et al.	
	HG	US-2005/0119273 A1	06/02/2005	Lipford, et al.	
	HH	US-2005/0123523 A1	06/09/2005	Krieg, et al.	
	HI	US-2005/0130911 A1	06/16/2005	Uhlmann, et al.	
	HJ	US-2005/0130918 A1	06/16/2005	Agrawal, et al.	
	HK	US-2005/0148537 A1	07/07/2005	Krieg, et al.	
	HL	US-2005/0169888 A1	08/04/2005	Hartman, et al.	
	HM	US-2005/0171047 A1	08/04/2005	Krieg, et al.	
	HN	US-2005/0176672 A1	08/11/2005	Scheule, et al.	
	HO	US-2005/0181035 A1	08/18/2005	Dow, et al.	
	HP	US-2005/0181422 A1	08/18/2005	Bauer, et al.	
	HQ	US-2005/0182017 A1	08/18/2005	Krieg	
	HR	US-2005/0191342 A1	09/01/2005	Tam, et al.	
	HS	US-2005/0197314 A1	09/08/2005	Krieg, et al.	
	HT	US-2005/0209184 A1	09/22/2005	Klinman, et al.	
	HU	US-2005/0214355	09/29/2005	Klinman, et al.	
	HV	US-2005/0215500 A1	09/29/2005	Krieg, et al.	
	HW	US-2005/0215501 A1	09/29/2005	Lipford, et al.	
	HX	US-2005/0233995 A1	10/20/2005	Krieg, et al.	
	HY	US-2005/0233999 A1	10/20/2005	Krieg, et al.	
	HZ	US-2005/0239732 A1	10/27/2005	Krieg, et al.	
	IA	US-2005/0239733 A1	10/27/2005	Jurk, et al.	
	IB	US-2005/0239734 A1	10/27/2005	Uhlmann, et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
				Examiner Name	HOLLERAN, Anne L.
Sheet	8	of	48	Attorney Docket Number	021819-000300US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	IC	US-2005/0239736 A1	10/27/2005	Krieg, et al.	
	ID	US-2005/0244379 A1	11/03/2005	Krieg, et al.	
	IE	US-2005/0244380 A1	11/03/2005	Krieg, et al.	
	IF	US-2005/0245477 A1	11/03/2005	Krieg, et al.	
	IG	US-2005/0249794 A1	11/10/2005	Semple, et al.	
	IH	US-2005/0250728 A1	11/10/2005	Krieg, et al.	
	II	US-2005/0256073 A1	11/17/2005	Lipford, et al.	
	IJ	US-2005/0266015 A1	12/01/2005	Clerici, et al.	
	IK	US-2005/0267057 A1	12/01/2005	Krieg	
	IL	US-2005/0267064 A1	12/01/2005	Krieg, et al.	
	IM	US-2005/0277604 A1	12/15/2005	Krieg, et al.	
	IN	US-2005/0277609 A1	12/15/2005	Krieg, et al.	
	IO	US-2006/0003955 A1	01/05/2006	Krieg, et al.	
	IP	US-2006/0003962 A1	01/05/2006	Ahluwalia, et al.	
	IQ	US-2006/0014713 A1	01/19/2006	Agrawal, et al.	
	IR	US-2006/0019909 A1	01/26/2006	Agrawal, et al.	
	IS	US-2006/0019916 A1	01/26/2006	Agrawal, et al.	
	IT	US-2006/0019923 A1	01/26/2006	Davis, et al.	
	IU	US-2006/0058251 A1	03/16/2006	Krieg, et al.	
	IV	US-2006/0074040 A1	04/06/2006	Kandimala, et al.	
	IW	US-2006/0089326 A1	04/27/2006	Krieg, et al.	
	IX	US-2006/0094683 A1	05/04/2006	Krieg, et al.	
	IY	US-2006/0140875 A1	06/29/2006	Krieg, et al.	
	IZ	US-2006/0154890 A1	07/13/2006	Bratzler, et al.	
	JA	US-2006/0172966 A1	08/03/2006	Lipford, et al.	
	JB	US-2006/0188913 A1	08/24/2006	Krieg, et al.	
	JC	US-2006/0189550 A1	08/24/2006	Jiang, et al.	
	JD	US-2006/0211639 A1	09/21/2006	Bratzler, et al.	
	JE	US-2006/0211641 A1	09/21/2006	Agrawal, et al.	
	JF	US-2006/0211644 A1	09/21/2006	Krieg, et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/621,254	
				Filing Date		July 14, 2003	
				First Named Inventor		Dow, Steven W.	
				Art Unit		1643	
				Examiner Name		HOLLERAN, Anne L.	
Sheet	9	of	48	Attorney Docket Number		021819-000300US	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	JG	US-2006/0223769	A1	10/05/2006	Dow, et al.	
	JH	US-2006/0229271	A1	10/12/2006	Krieg, et al.	
	JI	US-2006/0241076	A1	10/26/2006	Uhlmann, et al.	
	JJ	US-2006/0246035	A1	11/02/2006	Ahluwallia, et al.	
	JK	US-2006/0251623	A1	11/09/2006	Bachmann, et al.	
	JL	US-2006/0251677	A1	11/09/2006	Bachmann, et al.	
	JM	US-2006/0286070	A1	12/21/2006	Hartmann, et al.	
	JN	US-				
	JO	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	JP	PCT	WO90/14822	A1	12/13/1990	Northwestern University		<input type="checkbox"/>
	JQ	PCT	WO91/012811	A1	09/05/1991	Isis Pharmaceuticals, Inc.		<input type="checkbox"/>
	JR	PCT	WO92/03456	A1	03/05/1992	Isis Pharmaceuticals, Inc.		<input type="checkbox"/>
	JS	PCT	WO92/18522		10/1992			<input type="checkbox"/>
	JT	PCT	WO92/21353		12/1992			<input type="checkbox"/>
	JU	PCT	WO93/25673	A1	12/23/1993	The Regents of the University of California		<input type="checkbox"/>
	JV	PCT	WO94/04196	A1	03/03/1994	Imperial Cancer Research Technology Limited		<input type="checkbox"/>
	JW	PCT	WO94/019945	A1	09/15/1994	Isis Pharmaceuticals, Inc.		<input type="checkbox"/>
	JX	PCT	WO95/05853		03/1995			<input type="checkbox"/>
	JY	PCT	WO95/17507	A1	06/29/1995	Biognostik Gesellschaft für Biomolekulare Diagnostik MBH (DE)		<input type="checkbox"/>
	JZ	PCT	WO95/24929	A2	09/21/1995	Brown University Research Foundation		<input type="checkbox"/>
	KA	PCT	WO95/26204		10/1995			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/621,254	
				Filing Date		July 14, 2003	
				First Named Inventor		Dow, Steven W.	
				Art Unit		1643	
				Examiner Name		HOLLERAN, Anne L.	
Sheet	10	of	48	Attorney Docket Number		021819-000300US	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ²	Number ³	Kind Code ² (if known)				
	KB	PCT	WO/99/02555	A1	02/01/1996	University of Iowa Research Foundation		<input type="checkbox"/>
	KC	PCT	WO96/02560	A1	02/01/1996	University of North Carolina at Chapel Hill		<input type="checkbox"/>
	KD	PCT	WO96/35782		11/1996			<input type="checkbox"/>
	KE	PCT	WO96/40162	A1	12/19/1996	East Carolina University		<input type="checkbox"/>
	KF	PCT	WO97/03702	A1	02/06/1997	Brown University Research Foundation		<input type="checkbox"/>
	KG	PCT	WO97/28259	A1	06/07/1997	Regents of the University of California		<input type="checkbox"/>
	KH	PCT	WO97/30731	A3	08/28/1997	The Immune Response Corporation		<input type="checkbox"/>
	KI	PCT	WO98/11211	A2	03/19/1998	Hybridon, et al.		<input type="checkbox"/>
	KJ	PCT	WO98/14210	A2	03/19/1998	Hybridon, et al.		<input type="checkbox"/>
	KK	PCT	WO98/16247	A	04/23/1998	Regents of the University of California Regents of the University of California		<input type="checkbox"/>
	KL	PCT	WO98/18810	A1	05/07/1998	University of Iowa Research Foundation		<input type="checkbox"/>
	KM	PCT	WO98/29557	A1	07/09/1998	Biovect Therapeutics		<input type="checkbox"/>
	KN	PCT	WO98/32462	A1	07/30/1998	Wagner, et al.		<input type="checkbox"/>
	KO	PCT	WO98/49288	A1	11/05/1998	Hybridon, et al.		<input type="checkbox"/>
	KP	PCT	WO/98/51278	A2	11/19/1998	INEX Pharmaceuticals Corp.		<input type="checkbox"/>
	KQ	PCT	WO/98/52962	A1	11/28/1998	Merck and Co., Inc.		<input type="checkbox"/>
	KR	PCT	WO/98/55495	A2	12/10/1998	Dynavax Technologies Corp.		<input type="checkbox"/>
	KS	PCT	WO99/30686	A1	06/24/1999	INEX Pharmaceuticals Corp.		<input type="checkbox"/>
	KT	PCT	WO99/33488	A2	07/08/1999	SmithKline Beecham Biologicals S.A.		<input type="checkbox"/>
	KU	PCT	WO99/33493	A1	07/08/1999	INEX Pharmaceuticals Corp.		<input type="checkbox"/>
	KV	PCT	WO99/43360	A1	09/02/1999	OMI Corporation		<input type="checkbox"/>
	KW	PCT	WO99/52549	A1	10/29/1999	SmithKline Beecham Biologicals S.A.		<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number		10/621,254
				Filing Date		July 14, 2003
				First Named Inventor		Dow, Steven W.
				Art Unit		1643
				Examiner Name		HOLLERAN, Anne L.
Sheet	11	of	48	Attorney Docket Number		021819-000300US

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ²
		Country Code ²	Number ¹	Kind Code ² (if known)				
	KX	PCT	WO99/55743	A1	11/04/1999	INEX Pharmaceuticals Corp.		<input type="checkbox"/>
	KY	PCT	WO99/56755	A1	11/11/1999	University of Iowa Research Foundation		<input type="checkbox"/>
	KZ	PCT	WO99/58118	A2	11/18/1999	CPG Immunopharmaceuticals GMBH		<input type="checkbox"/>
	LA	PCT	WO99/61056	A3	12/02/1999	Loeb Health Research Institute at the Ottawa Hospital		<input type="checkbox"/>
	LB	PCT	WO00/03683	A2	01/27/2000	INEX Pharmaceuticals Corp.		<input type="checkbox"/>
	LC	PCT	WO00/06588	A1	02/10/2000	University of Iowa Research Foundation		<input type="checkbox"/>
	LD	PCT	WO00/15256	A2	03/23/2000	Pasteur Merieux Serums Et Vaccins [FR]		<input type="checkbox"/>
	LE	PCT	WO00/45849	A2	08/10/2000	Genzyme Corporation		<input type="checkbox"/>
	LF	PCT	WO00/46365	A1	08/10/2000	Virginia Commonwealth University		<input type="checkbox"/>
	LG	PCT	WO00/54803	A2	09/21/2000	Panacea Pharmaceuticals, LLC		<input type="checkbox"/>
	LH	PCT	WO00/61151	A2	10/19/2000	The Government of the United States of America		<input type="checkbox"/>
	LI	PCT	WO00/67787	A2	11/16/2000	The Immune Response Corporation		<input type="checkbox"/>
	LJ	PCT	WO00/75304	A1	12/14/2000	Aventis Pasteur [FR]		<input type="checkbox"/>
	LK	PCT	WO01/22972	A2	04/05/2001	Coley Pharmaceuticals, GmbH		<input type="checkbox"/>
	LL	PCT	WO01/35991	A2	05/25/2001	Dynavax Technologies Corp.		<input type="checkbox"/>
	LM	PCT	WO01/45750	A1	06/28/2001	The Regents of the University of California		<input type="checkbox"/>
	LN	PCT	WO01/68143	A2	09/20/2001	Dynavax Technologies Corp.		<input type="checkbox"/>
	LO	PCT	WO01/68144	A2	09/20/2001	Dynavax Technologies Corp.		<input type="checkbox"/>
	LP	PCT	WO01/83503	A2	11/08/2001	Hybridon, Inc.		<input type="checkbox"/>
	LQ	PCT	WO01/85751	A1	11/15/2001	Reliable Pharmaceutical, Inc.		<input type="checkbox"/>
	LR	PCT	WO01/83902	A2	12/13/2001	Biosynex Incorporated		<input type="checkbox"/>
	LS	PCT	WO02/26757	A2	04/04/2002	Hybridon, Inc.		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known Application Number 10/621,254 Filing Date July 14, 2003 First Named Inventor Dow, Steven W. Art Unit 1643 Examiner Name HOLLERAN, Anne L. Attorney Docket Number 021819-000300US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	12	of	48		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ²	Number ³	Kind Code ² (if known)				
	LT	PCT	WO02/28428	A2	04/11/2002	Aventis Pasteur [FR]		<input type="checkbox"/>
	LU	PCT	WO02/036767	A3	05/10/2002	INEX Pharmaceuticals Corp.		<input type="checkbox"/>
	LV	PCT	WO03/000232	A2	01/03/2003	Dynavax Technologies Corp.		<input type="checkbox"/>
	LW	PCT	WO03/002065	A2	01/09/2003	Chiron Corporation		<input type="checkbox"/>
	LX	PCT	WO03/024481	A2	03/27/2003	Cytos Biotechnology AG		<input type="checkbox"/>
	LY	PCT	WO03/026688	A1	04/03/2003	Pharmaderm Laboratories, Ltd.		<input type="checkbox"/>
	LZ	PCT	WO03/035836	A2	05/01/2003	Hybridon, Inc.		<input type="checkbox"/>
	MA	PCT	WO03/057822	A3	07/17/2003	Hybridon, Inc.		<input type="checkbox"/>
	MB	PCT	WO03/066649	A1	08/14/2003	Biomira Inc.		<input type="checkbox"/>
	MC	PCT	WO03/94963	A2	11/20/2003	INEX Pharmaceuticals Corp.		<input type="checkbox"/>
	MD	PCT	WO04/007743	A2	01/22/2004	Coley Pharmaceutical GmbH		<input type="checkbox"/>
	ME	PCT	WO04/026888	A2	04/01/2004	Coley Pharmaceutical GmbH		<input type="checkbox"/>
	MF	PCT	WO04/041183	A2	05/21/2004	The Regents of the University of California		<input type="checkbox"/>
	MG	PCT	WO04/058159	A2	07/15/2004	Dynavax Technologies Corp.		<input type="checkbox"/>
	MH	PCT	WO04/094671	A2	11/04/2004	Coley Pharmaceutical GmbH		<input type="checkbox"/>
	MI	PCT	WO05/001055	A2	01/06/2005	Hybridon, Inc.		<input type="checkbox"/>
	MJ	PCT	WO05/004907	A1	01/20/2005	Cytos Biotechnology AG		<input type="checkbox"/>
	MK	PCT	WO05/004910	A2	01/20/2005	Intercell Ag		<input type="checkbox"/>
	ML	PCT	WO05/023289	A1	03/17/2005	Intellectual Property Consulting Incorporated		<input type="checkbox"/>
	MM	PCT	WO06/002038	A2	01/05/2006	Hybridon, Inc.		<input type="checkbox"/>
	MN	PCT	WO06/012896	A1	02/09/2006	Universitätsklinikum Schleswig-Holstein		<input type="checkbox"/>
	MO	PCT	WO06/015872	A1	02/16/2006	Mologen Ag		<input type="checkbox"/>
	MP	EP	0302758	B1	3/1994			<input type="checkbox"/>
	MQ	EP	0468520	A3	01/1992			<input type="checkbox"/>
Examiner Signature						Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
				Examiner Name	HOLLERAN, Anne L.
Sheet	13	of	48	Attorney Docket Number	021819-000300US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	MR	EP	0773295	A	05/14/1997	Ottawa Civic Hospital		<input type="checkbox"/>
	MS	EP	0092574	A1	04/28/1983	Molecular Biosystems, Inc.		<input type="checkbox"/>
	MT	EP	0819758	A2	01/21/1998	Mixson		<input type="checkbox"/>
	MU	EP	1393745	A1	03/03/2004	Hybridon, Inc.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
	MV	[No author listed] CpG 7909: PF 3512676, PF-3512676. <i>Drugs R.D.</i> (2006) 7(5):312-316					<input type="checkbox"/>
	MW	Press Release, Hybridon, Inc. "Hybridon shows immunomodulatory activity of synthetic oligonucleotides", Cambridge, MA, May 7, 2001					<input type="checkbox"/>
	MX	ADYA, N., et al. "Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB", <i>Proc Natl Acad Sci USA</i> (1994) 91(12):5642-5646					<input type="checkbox"/>
	MY	AGRAWAL, S., et al. "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice", <i>Proceedings of the National Academy of Sciences</i> (1991) 88:7595-7599					<input type="checkbox"/>
	MZ	AGRAWAL, S., et al. "Pharmacokinetics of antisense oligonucleotides", <i>Clin Pharmacokinetics</i> (1995) 28(1):7-16					<input type="checkbox"/>
	NA	AGRAWAL, S., et al. "Medicinal chemistry and therapeutic potential of CpG DNA", <i>Trends Mol Med.</i> (2002) 8(3):114-121					<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/621,254
		Filing Date	July 14, 2003
		First Named Inventor	Dow, Steven W.
		Art Unit	1643
		Examiner Name	HOLLERAN, Anne L.
		Attorney Docket Number	021819-000300US
Sheet	14	of	48

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	NB	AGRAWAL, S., et al. "Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma", <i>Int Immunopharmacol</i> (2004) 4(1):127-138	<input type="checkbox"/>
	NC	ALPAR, et al. "Potential of particulate carriers for the mucosal delivery of DNA vaccines", <i>Biochem Soc Trans</i> (1997) 25(2):337S	<input type="checkbox"/>
	ND	ANFOSSI, et al. HCAPLUS Database, AN: 475562, Abstract. 1989	<input type="checkbox"/>
	NE	ANGIER, N., "Microbe DNA seen as alien by immune system", <i>New York Times</i> , April 11, 1995	<input type="checkbox"/>
	NF	ANITESCU, et al. "Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12", <i>J Interferon Cytokine Res.</i> (1997) 17(12):781-788	<input type="checkbox"/>
	NG	ASKEW, et al. "CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms", <i>J Immunol.</i> (2000) 165(12):6889-6895	<input type="checkbox"/>
	NH	AZAD, R.F., et al. "Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-Early Region", <i>Antimicrobial Agents and Chemotherapy</i> (1993) 37:1945-1954	<input type="checkbox"/>
	NI	AZUMA, I. "Biochemical and Immunological Studies on Cellular Components of Tubercle Bacilli", <i>Kekkaku</i> (1992) 67(9):45-55	<input type="checkbox"/>
	NJ	BARAL, et al. "Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotypic vaccine that mimics carcinoembryonic antigen", <i>Cancer Immunol Immunother.</i> (2003) 52(5):317-327	<input type="checkbox"/>
	NK	BAUER, et al. "DNA activates human immune cells through a CpG sequence-dependent manner", <i>Immunology</i> (1999) 97(4):699-705	<input type="checkbox"/>
	NL	BAUER, et al. "Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition", <i>Proc Natl Acad Sci U S A</i> (2001) 98(16):9237-9242	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known Application Number 10/621,254 Filing Date July 14, 2003 First Named Inventor Dow, Steven W. Art Unit 1643 Examiner Name HOLLERAN, Anne L. Attorney Docket Number 021819-000300US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	15	of	48		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	NM	BAYEVER, et al. "Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial", <i>Antisense Res Dev.</i> (1993) 3(4):383-390	<input type="checkbox"/>		
	NN	BENNETT, C.F. "Intracellular Delivery of Oligonucleotides with Cationic Liposomes", <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , (1995) Akthar, Ed.: 223-32 (Abstract)	<input type="checkbox"/>		
	NO	BENNETT, R.M., et al. "DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA", <i>J Clin Invest</i> (1985) 76(6):2182-2190	<input type="checkbox"/>		
	NP	BIANCO, et al. "Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties", <i>J Am Chem Soc.</i> (2005) 127(1):58-59	<input type="checkbox"/>		
	NQ	BIOLABS 1988-1989 Catalog, Random Primer #s 1230, 1601, 1602	<input type="checkbox"/>		
	NR	BLAXTER, et al. "Genes expressed in <i>Brugia malayi</i> infective third stage larvae", <i>Molecular and Biochemical Parasitology</i> (1996) 77:77-93	<input type="checkbox"/>		
	NS	BLAZAR, et al. "Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naïve and bone marrow transplant recipients", <i>Blood</i> (2001) 98(4):1217-1225	<input type="checkbox"/>		
	NT	BOGGS, et al. "Characterization and modulation of immune stimulation by modified oligonucleotides", <i>Antisense Nucleic Acid Drug Dev</i> (1997) 7(5):461-471	<input type="checkbox"/>		
	NU	BOWERSOCK, et al. "Evaluation of an orally administered vaccine, using hydrogels containing bacterial exotoxins of <i>Pasteurella haemolytica</i> , in cattle", <i>Am J Vet Res</i> (1994) 55(4):502-509	<input type="checkbox"/>		
	NV	BRANDA, R.F., et al. "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1", <i>Biochemical Pharmacology</i> (1993) 45(10):2037-2043	<input type="checkbox"/>		
	NW	BRANDA, et al. "B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1", <i>Clin Immunol Immunopathol</i> (1996) 79(2):115-121	<input type="checkbox"/>		
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
Art Unit		1643			
Examiner Name		HOLLERAN, Anne L.			
Attorney Docket Number		021819-000300US			
Sheet	16	of	48		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	NX	BRANDA, et al "Amplification of antibody production by phosphorothioate oligodeoxynucleotides", <i>J Lab Clin Med</i> (1996) 128(3):329-338	<input type="checkbox"/>	
	NY	BRIGNOLE, et al. "Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myc antisense oligonucleotides containing CpG motifs", <i>J Natl Cancer Inst</i> (2004) 96(15):1171-1180	<input type="checkbox"/>	
	NZ	BRISKIN, M., et al. "Lipopolysaccharide - unresponsive mutant pre-B-cell lines blocked in NF-kappa B Activation", <i>Mol Cell Biol</i> (1990) 10(1):422-425	<input type="checkbox"/>	
	OA	BROIDE, et al. "Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice", <i>J Immunol.</i> (1998) 161(12):7054-7062	<input type="checkbox"/>	
	OB	BROIDE, et al. "DNA-based immunization for asthma", <i>Int Arch Allergy Immunol.</i> (1999) 118(2-4):453-456	<input type="checkbox"/>	
	OC	BRUNNER, et al. "Enhanced dendritic cell maturation by TNF-alpha or cytidine-hosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo", <i>J Immunol.</i> (2000) 165(11):6278-6286	<input type="checkbox"/>	
	OD	CARPENTIER, et al. "Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs", <i>Clin Cancer Res.</i> (2000) 6(6):2469-2473	<input type="checkbox"/>	
	OE	CHACE, et al. "Regulation of Differentiation in CD5+ and Conventional B Cells", <i>Clinical Immunology and Immunopathology</i> (1993) 68(3):237-332	<input type="checkbox"/>	
	OF	CHACE, et al. "Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12", <i>Clin Immunol Immunopathol</i> (1997) 84(2):185-193	<input type="checkbox"/>	
	OG	CHAN, et al. "CpG-A and CpG-B oligodeoxynucleotides differentially affect the cytokine profile, chemokine receptor expression and T-cell priming function of human plasmacytoid dendritic cells", <i>Blood</i> (2002) 11:50b. Abstract #3666	<input type="checkbox"/>	
	OH	CHANG, Y.N., et al. "The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements", <i>J Virol</i> (1990) 64(1):264-277	<input type="checkbox"/>	
Examiner Signature			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/621,254
				<i>Filing Date</i>	July 14, 2003
				<i>First Named Inventor</i>	Dow, Steven W.
				<i>Art Unit</i>	1643
				<i>Examiner Name</i>	HOLLERAN, Anne L.
(Use as many sheets as necessary)				<i>Attorney Docket Number</i>	021819-000300US
Sheet	17	of	48		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	OI	CHANG, et al. "The effect of CpG-oligodeoxynucleotides with different backbone structures and 3' hexameric deoxyriboguanosine run conjugation on the treatment of asthma in mice", <i>J Allergy Clin Immunol.</i> (2004) 113(2):S323. Abstract 1196	<input type="checkbox"/>		
	OJ	CHATURVERDI, et al. "Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages", <i>Nucleic Acids Res.</i> (1996) 24(12):2318-2323	<input type="checkbox"/>		
	OK	CHEN, et al. "Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles", <i>J. Virol.</i> (1998) 72(7):5757-5761	<input type="checkbox"/>		
	OL	CHOI, et al. "The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant", <i>Vaccine</i> (2002) 20(13-14):1733-1740	<input type="checkbox"/>		
	OM	CHU, R.S., et al. "CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity", <i>J Exp Med</i> (1997) 186(10):1623-1631	<input type="checkbox"/>		
	ON	COHEN "Selective anti-gene therapy for cancer: principles and prospects", <i>Tohoku J Exp Med.</i> (1992) 168(2):351-359	<input type="checkbox"/>		
	OO	COOPER, et al. "Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluorix influenza vaccine", <i>Vaccine</i> (2004) 22(23-24):3136-3143	<input type="checkbox"/>		
	OP	COSSUM, et al. "Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats", <i>J Pharmacol Exp Ther</i> (1993) 267(3):1181-1190	<input type="checkbox"/>		
	OQ	COWDERY, et al. "Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides", <i>J Immunol.</i> (1996) 156(12):4570-4575	<input type="checkbox"/>		
	OR	COWSERT, et al. "In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts", <i>Antimicrob Agents Chemother</i> (1993) 37(2):171-177	<input type="checkbox"/>		
	OS	CROOKE, et al. "Phosphorothioate Oligonucleotides", <i>Therapeut Apps.</i> (1995) Ch5:63-84	<input type="checkbox"/>		
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		<i>Application Number</i>	10/621,254
		<i>Filing Date</i>	July 14, 2003
		<i>First Named Inventor</i>	Dow, Steven W.
		<i>Art Unit</i>	1643
		<i>Examiner Name</i>	HOLLERAN, Anne L.
		<i>Attorney Docket Number</i>	021819-000300US
Sheet	18	of	48

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	OT	CROSBY, et al. "The Early Responses Gene FGF1-C Encodes a Zinc Finger Transcriptional Activator and is a Member of the GCGGGGGCG (GSG) Element-Binding Protein Family" <i>Mol. Cell Biol.</i> (1991) 2:3835-3841	<input type="checkbox"/>
	OU	CRYSTAL "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", <i>Science</i> (1995) 270:404-410	<input type="checkbox"/>
	OV	CRYZ, et al. "European Commission COST/STD Initiative. Report of the expert panel VII. Vaccine delivery systems", <i>Vaccine</i> (1996) 14(7):665-690	<input type="checkbox"/>
	OW	DAFTARIAN, et al. "Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors", <i>Cancer Res.</i> (2004) 64(15):5407-5414	<input type="checkbox"/>
	OX	DAHESHA, et al. "Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines", <i>Vaccine</i> (1998) 16(11-12):1103-1110	<input type="checkbox"/>
	OY	DALPKE, et al. "CpG-DNA as immune response modifier", <i>Int J Med Microbiol</i> (2004) 294(5):345-354	<input type="checkbox"/>
	OZ	DASS, et al. "Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer", <i>J Cancer Res Clin Oncol</i> (2002) 128(4):177-181	<input type="checkbox"/>
	PA	DAVILA, et al. "Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade", <i>Cancer Res.</i> (2003) 63(12):3281-3288	<input type="checkbox"/>
	PB	DAVIS et al. <i>Journal of Immunology</i> (1998) 160:870-876	<input type="checkbox"/>
	PC	DAVIS, "Use of CpG DNA for enhancing specific immune responses", <i>Curr Top Microbiol Immunol.</i> (2000) 247:171-183	<input type="checkbox"/>
	PD	DAVIS, et al. "CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909", <i>Third Annual Conference on Vaccine Res.</i> (2000) Abstract s25, number 47	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/621,254
		Filing Date	July 14, 2003
		First Named Inventor	Dow, Steven W.
		Art Unit	1643
		Examiner Name	HOLLERAN, Anne L.
		Attorney Docket Number	021819-000300US
Sheet	19	of	48

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	PE	DELONG, et al. "Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery", <i>J Pharm Sci.</i> (1997) 86(6):762-764	<input type="checkbox"/>
	PF	DOW, et al. "Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously", <i>J Immunology</i> (1999) 163(3):1552-1561	<input type="checkbox"/>
	PG	DRYGA, et al. <i>Vopr. Virusol.</i> (41(3):100-104	<input type="checkbox"/>
	PH	ELDRIDGE, et al. "Biodegradable microspheres as a vaccine delivery system", <i>Mol Immunol.</i> (1991) 28(3):287-294. Abstract Only	<input type="checkbox"/>
	PI	EMI, et al. "Gene transfer mediated by polyarginine requires a formation of big carrier-complex of DNA aggregate", <i>Biochem Biophys Res Commun.</i> (1997) 231(2):421-424	<input type="checkbox"/>
	PJ	ENGLISCH, et al. "Chemically Modified Oligonucleotides as Probes and Inhibitors", <i>Angew Chem. Int. Ed. Engl.</i> (1991) 30:613-629	<input type="checkbox"/>
	PK	ERB, K.J., et al. "Infection of mice with <i>Mycobacterium bovis</i> - <i>Bacillus Calmette-Guerin</i> (BCG) suppresses allergen-induced airway eosinophilia", <i>J Exp Med</i> (1998) 187(4):561-569	<input type="checkbox"/>
	PL	ETLINGER, "Carrier sequence selection - one key to successful vaccines", <i>Immunology Today</i> (1992) 13(2):52-55	<input type="checkbox"/>
	PM	FILION, et al. "Major limitations in the use of cationic liposomes for DNA delivery", <i>Int J Pharmaceut</i> (1998) 162:159-170	<input type="checkbox"/>
	PN	FOX, R.I. "Mechanism of action of hydroxychloroquine as an antirheumatic drug", <i>Chemical Abstracts</i> (1994) 120:15, Abstract No. 182630	<input type="checkbox"/>
	PO	FRALEY, et al. "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", <i>Trends Biochem Sci.</i> (1981) 6:77-80	<input type="checkbox"/>
Examiner Signature			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/621,254
				<i>Filing Date</i>	July 14, 2003
				<i>First Named Inventor</i>	Dow, Steven W.
				<i>Art Unit</i>	1643
				<i>Examiner Name</i>	HOLLERAN, Anne L.
<i>(Use as many sheets as necessary)</i>					
Sheet	20	of	48	<i>Attorney Docket Number</i>	021819-000300US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	PP	FRANCOIS, D.T., et al. "Examination of the inhibitory and stimulatory effects of IFN- α , - β , and - γ on human B-Cell proliferation induced by various B-Cell mitogens", <i>Clinical Immunology and Immunopathology</i> (1988) 48:297-306	<input type="checkbox"/>		
	PQ	GALLICHAN, et al. "Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus", <i>Vaccine</i> (1995) 13(16):1589-1595	<input type="checkbox"/>		
	PR	GALLICHAN, et al. "Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract", <i>J Immunol.</i> (2001) 166(5):3451-3457	<input type="checkbox"/>		
	PS	GAO, ET AL. "Bacterial DNA and lipopolysaccharide induce synergistic production of TNF- α through a post-transcriptional mechanism", <i>J Immunol.</i> (2001) 166(11):6855-6860	<input type="checkbox"/>		
	PT	GARBI, et al. "CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction", <i>J Immunol.</i> (2004) 172(10):5861-5869	<input type="checkbox"/>		
	PU	GAREGG, et al. "Nucleoside H-phosphonates. IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach", <i>Tetrahedron Lett.</i> (1986) 27(34):4055-4058	<input type="checkbox"/>		
	PV	GASTON, et al. "CpG methylation has differential effects on the binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes", <i>Nucleic Acids Res.</i> (1995) 23(6):901-909	<input type="checkbox"/>		
	PW	GEISSLER, et al. "Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids", <i>J Immunol</i> (1997) 158(3):1231-1237	<input type="checkbox"/>		
	PX	GOODMAN, et al. "Selective modulation of elements of the immune system by low molecular weight nucleosides", <i>J Pharmacol Exp Ther.</i> (1995) 274(3):1552-1557	<input type="checkbox"/>		
	PY	GOUTTEFANGEAS, et al. "Problem solving for tumor immunotherapy", <i>Nat Biotechnol.</i> (2000) 18(5):491-492	<input type="checkbox"/>		
	PZ	GREGORIADIS, et al. "Liposomes for drugs and vaccines", <i>Trends Biotechnol.</i> (1985) 3:235-241	<input type="checkbox"/>		
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/621,254
		Filing Date	July 14, 2003
		First Named Inventor	Dow, Steven W.
		Art Unit	1643
		Examiner Name	HOLLERAN, Anne L.
		Attorney Docket Number	021819-000300US
Sheet	21	of	48

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	QA	GREGORIADIS "Immunological adjuvants: a role of liposomes", <i>Immunology Today</i> (1990) 11(3):89-97	<input type="checkbox"/>
	QB	GREGORIADIS, et al. "Engineering liposomes for drug delivery: progress and problems", <i>Trends Biotechnol.</i> (1995) 13(12):527-537	<input type="checkbox"/>
	QC	GROSSMANN, et al. "Avoiding tolerance against prostatic antigens with subdominant peptide epitopes", <i>J Immunother.</i> (2001) 24(3):237-241	<input type="checkbox"/>
	QD	GURA, T., "Antisense has growing pains", <i>Science</i> (1995) 270:575-576	<input type="checkbox"/>
	QE	GURSEL, et al. "Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide", <i>J Leukoc Biol.</i> (2002) 71(5):813-820	<input type="checkbox"/>
	QF	GURSEL, et al. "Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides", <i>J Immunol.</i> (2001) 167(6):3324-3328	<input type="checkbox"/>
	QG	HADDEN, et al. "Immunostimulants", <i>Trends Pharmacol Sci.</i> (1993) 141:169-174	<input type="checkbox"/>
	QH	HADDEN, et al. "Immunopharmacology", <i>JAMA</i> (1992) 268(20):2964-2969	<input type="checkbox"/>
	QI	HAFNER, et al. "Antimetastatic effect of CpG DNA mediated by type I IFN", <i>Cancer Res.</i> (2001) 61(14):5523-5528	<input type="checkbox"/>
	QJ	HAHM, et al. "Efficacy of polyadenylic-polyuridylic acid in the treatment of chronic active hepatitis B", <i>Int J Immunopharmacol.</i> (1994) 16(3):217-225	<input type="checkbox"/>
	QK	HALPERN, et al. "Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha", <i>Cell Immunol.</i> (1996) 167(1):72-78	<input type="checkbox"/>
Examiner Signature			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		
				10/621,254		
				Filing Date		
				July 14, 2003		
				First Named Inventor		
				Dow, Steven W.		
				Art Unit		
				1643		
				Examiner Name		
				HOLLERAN, Anne L.		
Sheet				22	of	48
				Attorney Docket Number		
				021819-000300US		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	QL	HANEBERG, et al. "Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces", <i>Infect. Immun.</i> 62(1):15-23	<input type="checkbox"/>	
	QM	HARRINGTON, et al. "Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine", <i>Infect Immun.</i> (1979) 24(1):160-166	<input type="checkbox"/>	
	QN	HARTMANN, et al. "CpG DNA and LPS induce distinct patterns of activation in human monocytes", <i>Gene Ther.</i> (1999) 6(5):893-903	<input type="checkbox"/>	
	QO	HARTMANN, et al. "Mechanism and function of a newly identified CpG DNA motif in human primary B cells", <i>J. Immunol</i> (2000) 164(2):944-953	<input type="checkbox"/>	
	QP	HARTMANN, et al. "Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes", <i>J Pharmacol Exp Ther.</i> (1998) 285(2):920-928	<input type="checkbox"/>	
	QQ	HARTMANN, et al. "Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo", <i>J Immunol.</i> (2000) 164(3):1617-1624	<input type="checkbox"/>	
	QR	HARTMANN, et al. "CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells", <i>Proc Natl Acad Sci USA</i> (1999) 96(16):9305-9310	<input type="checkbox"/>	
	QS	HATZFELD, J., et al. "Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor β 1 or Rb Oligonucleotides", <i>J. Exp. Med.</i> , (1991) 174:925-929	<input type="checkbox"/>	
	QT	HAYNES, et al. "Particle-mediated nucleic acid immunization", <i>J Biotechnol.</i> (1996) 44(1-3):37-42	<input type="checkbox"/>	
	QU	HECKELSMILLER, et al. "Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model", <i>J Immunol.</i> (2002) 169(7):3892-3899	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
Art Unit		1643			
Examiner Name		HOLLERAN, Anne L.			
Attorney Docket Number		021819-000300US			
Sheet	23	of	48		

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	QV	HEEG, et al. "CpG DNA as a Th1 trigger", <i>Int Arch Allergy Immunol.</i> (2000) 121(2):87-97	<input type="checkbox"/>		
	QW	HENRY, et al. "Chemically modified oligonucleotides exhibit decreased immune stimulation in mice", <i>J Pharmacol Exp Ther.</i> (2000) 292(2):468-479	<input type="checkbox"/>		
	QX	HIGHFIELD, P.E., "Sepsis: the More, the Murkier", <i>Biotechnology</i> (1994) 12:828	<input type="checkbox"/>		
	QY	HIGAKI, et al. "Mechanisms involved in the inhibition of growth of a human B lymphoma cell line B104, by anti-MHC class II antibodies", <i>Immunol Cell Biol.</i> (1994) 72(3):205-214	<input type="checkbox"/>		
	QZ	HINKULA, et al. "Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type I regulatory genes", <i>J Virol</i> (1997) 71(7):5528-5539	<input type="checkbox"/>		
	RA	HOEFFLER, J.P., et al. "Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions", <i>Mol Endocrinol</i> (1991) 5(2):256-266	<input type="checkbox"/>		
	RB	HOPKIN, et al. "Curbing the CpGs of Bacterial and Viral DNA", <i>BioMedNet.</i> (1999) June 25; Issue 57	<input type="checkbox"/>		
	RC	HSU, <i>Nature Med.</i> (1996) 2(5):540-544	<input type="checkbox"/>		
	RD	HUANG, et al. "Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria", <i>Infect Immun.</i> (1999) 67(12):6257-6263	<input type="checkbox"/>		
	RE	HUDSON, et al. "Nucleic acid dendrimers: Novel biopolymer structures", <i>J Am Chem Soc.</i> (1993) 115:2119-2124	<input type="checkbox"/>		
	RF	HUNTER, et al. "Biodegradable microspheres containing group B-Streptococcus vaccine: immune response in mice", <i>Am J Obstet Gynecol.</i> (2001) 185(5):1174-1179	<input type="checkbox"/>		
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/621,254
		<i>Filing Date</i>	July 14, 2003
		<i>First Named Inventor</i>	Dow, Steven W.
		<i>Art Unit</i>	1643
		<i>Examiner Name</i>	HOLLERAN, Anne L.
		<i>Attorney Docket Number</i>	021819-000300US
Sheet	24	of	48

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	RG	IGUCHI-ARIGA, S.M., et al. "CpG methylation of the cAMP -responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding protein and as well as transcriptional activation", <i>Genes Dev</i> (1999) 3(5):612-619	<input type="checkbox"/>
	RH	IHO, et al. "Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro", <i>J Immunol.</i> (1999) 163(7):3642-3652	<input type="checkbox"/>
	RI	IOANNOU, et al. "The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxy nucleotides", <i>J Virol.</i> (2002) 76(18):9002-9010	<input type="checkbox"/>
	RJ	International Search Report for PCT/US95/01570 (July 5, 1995)	<input type="checkbox"/>
	RK	ISHIKAWA, R., et al. "IFN induction and associated changes in splenic leukocyte distribution", <i>J Immunol</i> (1993) 150(9):3713-3727	<input type="checkbox"/>
	RL	IVERSON, et al. "In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue", <i>Anticancer Drug Des.</i> (1991) 6(6):531-538	<input type="checkbox"/>
	RM	IVERSON, et al. "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion", <i>Antisense Res Dev.</i> (1994) 4(1):43-52	<input type="checkbox"/>
	RN	JACOBSON, et al. "Early viral response and on treatment response to CpG 10101 (ACTILON™), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. 57th Annual Meeting of American Association for the Study of the Liver Diseases (AASLD). 2006 Oct 30. Boston, Mass; presented Abstract #96	<input type="checkbox"/>
	RO	JAKOB, et al. "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA", <i>J Immunol.</i> (1998) 161(6):3042-3049	<input type="checkbox"/>
	RP	JAKOB, et al. "Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses", <i>Int Arch Allergy Immunol</i> (1999) 118(2-4):457-461	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/621,254
			<i>Filing Date</i>	July 14, 2003
			<i>First Named Inventor</i>	Dow, Steven W.
			<i>Art Unit</i>	1643
			<i>Examiner Name</i>	HOLLERAN, Anne L.
(Use as many sheets as necessary)			<i>Attorney Docket Number</i>	021819-000300US
Sheet	25	of	48	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	RQ	JAKWAY, J., et al. "Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products", <i>J. Immunol</i> (1996) 137(7):2225-2231	<input type="checkbox"/>	
	RR	JAROSZEWSKI, J., et al. "Cellular uptake of antisense oligonucleotides", <i>Adv Drug Delivery Rev</i> (1991) 6(3):235-250	<input type="checkbox"/>	
	RS	JASHKE, et al. "Automated incorporation of polyethylene glycol into synthetic oligonucleotides", <i>Tetrahedron Lett.</i> (1993) 34(2):301-304	<input type="checkbox"/>	
	RT	JIANG, et al. "Enhancing Immunogenicity by CpG DNA", <i>Curr Opin Mol Ther.</i> (2003) 5(2):180-185	<input type="checkbox"/>	
	RU	JIAO, et al. "Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes", <i>J Gen Virol</i> (2004) 85(Pt 6):1545-1553	<input type="checkbox"/>	
	RV	JOHNSON, et al. "Non-specific resistance against microbial infections induced by polyribonucleotide complexes. In: Immunopharmacology of infection diseases: Vaccine adjuvants and modulators of non-specific resistance (1987) 291-301	<input type="checkbox"/>	
	RW	JUFFERMANS, et al. "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis", <i>Infect Immun</i> (2002) 70(1):147-152	<input type="checkbox"/>	
	RX	KANDIMALLA, et al. "A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif", <i>Proc Natl Acad Sci USA</i> (2003) 100(24):14303-14308	<input type="checkbox"/>	
	RY	KANDIMALLA, et al. "Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships", <i>Bioorg Med Chem</i> (2001) 9(3):807-813	<input type="checkbox"/>	
	RZ	KANDIMALLA, et al. "Towards optimal design of second-generation immunomodulatory oligonucleotides", <i>Curr Opin Mol Ther</i> (2002) 4(2):122-129	<input type="checkbox"/>	
	SA	KANDIMALLA, et al. "Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles", <i>Nucleic Acids Res</i> (2003) 31(9):2393-2400	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
				Art Unit	
				1643	
				Examiner Name	
				HOLLERAN, Anne L.	
Sheet	26	of	48	Attorney Docket Number	
				021819-000300US	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	SB	KATAOKA, T., et al. "Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose", <i>Jpn J Med Sci Biol</i> (1990) 43(5):171-182	<input type="checkbox"/>	
	SC	KATAOKA, T., et al. "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG", <i>Japanese Journal of Cancer Research</i> (1992) 83:244-247	<input type="checkbox"/>	
	SD	KIMURA, Y., et al. "Binding of Oligoguanylate to Scavenger Receptors is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN", <i>J. Biochem</i> (1994) 116(5):991-994	<input type="checkbox"/>	
	SE	KLINE, J. N., et al. "CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma", <i>J Invest Med</i> (1996) 44(7):380A	<input type="checkbox"/>	
	SF	KLINE, J. N., et al. "CpG oligonucleotides can reverse as well as prevent TH2-mediated inflammation in a murine model of asthma", <i>J Invest Med</i> (1997) 45(7):298A	<input type="checkbox"/>	
	SG	KLINE, J. N., et al. "Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma", <i>J Invest Med.</i> (1997) 45(3):282A	<input type="checkbox"/>	
	SH	KLINE, et al. "Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma", <i>J Immunol.</i> (1998) 160(6):2555-2559	<input type="checkbox"/>	
	SI	KLINMAN, DM., et al. "CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma", <i>Proc Natl Acad Sci USA</i> (1996) 93(7):2879-2883	<input type="checkbox"/>	
	SJ	KLINMAN, et al. "Contribution of CpG motifs to the immunogenicity of DNA vaccines", <i>J Immunol.</i> (1997) 158(8):3635-3639	<input type="checkbox"/>	
	SK	KLINMAN, et al. "Immune recognition of foreign DNA: a cure for bioterrorism?" <i>Immunity</i> (1999) 11(2):123-129	<input type="checkbox"/>	
	SL	KLINMAN, et al. "Immunotherapeutic applications of CpG-containing oligodeoxynucleotides", <i>Drug News Perspect.</i> (2000) 13(5):289-296	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/621,254
				<i>Filing Date</i>	July 14, 2003
				<i>First Named Inventor</i>	Dow, Steven W.
				<i>Art Unit</i>	1643
				<i>Examiner Name</i>	HOLLERAN, Anne L.
<i>(Use as many sheets as necessary)</i>				<i>Attorney Docket Number</i>	021819-000300US
Sheet	27	of	48		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	SM	KLINMAN, et al "Immunotherapeutic uses of CpG oligodeoxynucleotides", <i>Nat Rev Immunol</i> (2004) 4(4):249-258			<input type="checkbox"/>
	SN	KNIPE, et al., eds., <i>Fields' Virology</i> (2001)1:1004-1016			<input type="checkbox"/>
	SO	KNIPE, et al., eds., <i>Fields' Virology</i> (2001)1:1564			<input type="checkbox"/>
	SP	KOVARIK, et al. "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming", <i>J. Immunol</i> (1999) 162(3):1611-1617			<input type="checkbox"/>
	SQ	KRANZER, et al. "CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type 1 and interleukin-12." <i>Immunology</i> (2000) 99(2):170-178			<input type="checkbox"/>
	SR	KRIEG, et al. "A role for endogenous retroviral sequences in the regulation of lymphocyte activation", <i>J Immunol.</i> (1989) 143(8):2448-2451			<input type="checkbox"/>
	SS	KRIEG, et al. "A role for endogenous retroviral sequences in the regulation of lymphocyte activation", <i>J Immunol.</i> (1989) 143(8):2448-2451			<input type="checkbox"/>
	ST	KRIEG, et al. "Uptake of oligodeoxynucleotides by lymphoid cells is heterogeneous and inducible", <i>Antisense Res Dev</i> (1991) 1(2):161-171			<input type="checkbox"/>
	SU	KRIEG, et al. "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", <i>Proc Natl Acad Sci USA</i> (1993) 90(3):1048-1052			<input type="checkbox"/>
	SV	KRIEG, et al. "Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs", American College of Rheumatology 58th National Scientific Meeting. Minneapolis, MN, October 22, 1994. Abstracts. <i>Arthritis Rheum.</i> (1994) 37(9 Suppl).			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known <i>Application Number</i> 10/621,254 <i>Filing Date</i> July 14, 2003 <i>First Named Inventor</i> Dow, Steven W. <i>Art Unit</i> 1643 <i>Examiner Name</i> HOLLERAN, Anne L. <i>Attorney Docket Number</i> 021819-000300US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	28	of	48		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	SW	KRIEG, et al. "Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?", <i>Antisense Res Dev.</i> (1995) 5(4):241	<input type="checkbox"/>	
	SX	KRIEG "CpG DNA: a pathogenic factor in systemic lupus erythematosus? <i>J Clin Immunol</i> (1995) 15(6):284-292	<input type="checkbox"/>	
	SY	KRIEG, et al. "Infection", in McGraw Hill Book. (1996) pp. 242-243	<input type="checkbox"/>	
	SZ	KRIEG, et al. "Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs", <i>Antisense Nucleic Acid Drug Dev</i> (1996) 6(2):133-139	<input type="checkbox"/>	
	TA	KRIEG, et al. "An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA", <i>J Lab Clin Med</i> (1996) 128(2):128-133	<input type="checkbox"/>	
	TB	KRIEG, et al. "Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge", <i>1996 Meeting on Molecular Approaches to the Control of Infectious Diseases</i> , Cold Spring Harbor Laboratory, (1996): 116	<input type="checkbox"/>	
	TC	KRIEG, et al. "Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge", <i>Vaccines</i> (1997) 97:77-79	<input type="checkbox"/>	
	TD	KRIEG, et al. "Leukocyte stimulation by oligodeoxynucleotides", <i>Applied Antisense Oligonucleotide Technology</i> (1998) pp. 431-448	<input type="checkbox"/>	
	TE	KRIEG, et al. "The role of CpG dinucleotides in DNA vaccines", <i>Trends in Microbiology</i> (1998) 6(1):23-27	<input type="checkbox"/>	
	TF	KRIEG, et al. "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs", <i>Proc Natl Acad Sci USA</i> (1998) 95(21):12631-12636	<input type="checkbox"/>	
	TG	KRIEG, et al. "The CpG motif: Implications for clinical immunology", <i>BioDrugs</i> (1998) 10(5):341-346	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/621,254
		<i>Filing Date</i>	July 14, 2003
		<i>First Named Inventor</i>	Dow, Steven W.
		<i>Art Unit</i>	1643
		<i>Examiner Name</i>	HOLLERAN, Anne L.
		<i>Attorney Docket Number</i>	021819-000300US
Sheet	29	of	48

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	TH	KRIEG, et al. Chapter 8: "Immune Stimulation by Oligonucleotides" in: <i>Antisense Research and Application</i> , Crooke, editor, (1998) pp. 243-262	<input type="checkbox"/>
	TI	KRIEG, et al. "CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge", <i>J Immunol.</i> (1998) 161(5):2428-2434	<input type="checkbox"/>
	TJ	KRIEG, et al. "Direct immunologic activities of CpG DNA and implications for gene therapy", <i>J Gene Med.</i> (1999) 1(1):56-63	<input type="checkbox"/>
	TK	KRIEG, et al. "Mechanisms and applications of immune stimulatory CpG oligodeoxy nucleotides", <i>Biochim Biophys Acta</i> (1999) 1489(1):107-116	<input type="checkbox"/>
	TL	KRIEG, et al. "Applications of immune stimulatory CpG DNA for antigen-specific and antigen-non-specific cancer immunotherapy", <i>Eur J Canc.</i> (1999) 35/Suppl4:S10. Abstract #14	<input type="checkbox"/>
	TM	KRIEG, et al. "How to exclude immunostimulatory and other nonantisense effects of antisense oligonucleotides", <i>Manual of Antisense</i> (1999) pp. 79-89	<input type="checkbox"/>
	TN	KRIEG, et al. "Mechanisms and therapeutic applications of immune stimulatory CpG DNA", <i>Pharmacol Ther.</i> (1999) 84(2):113-120	<input type="checkbox"/>
	TO	KRIEG, et al. "CpG DNA: a novel immunomodulator", <i>Trends Microbiol.</i> (1999) 7(2):64-65	<input type="checkbox"/>
	TP	KRIEG, et al. "The role of CpG motifs in innate immunity", <i>Curr Opin Immunol.</i> (2000) 12(1):35-43	<input type="checkbox"/>
	TQ	KRIEG, et al. "Signal transduction induced by immunostimulatory CpG DNA", <i>Springer Semin Immunopathol</i> (2000) 22(1-2):97-105	<input type="checkbox"/>
	TR	KRIEG, et al. "Rescue of B cells from apoptosis by immune stimulatory CpG DNA", <i>Springer Semin Immunopathol.</i> (2000) 22(1-2):55-61	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
Art Unit		1643			
Examiner Name		HOLLERAN, Anne L.			
Attorney Docket Number		021819-000300US			
Sheet	30	of	48		

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	TS	KRIEG, et al. "Mechanism of action of CpG DNA", <i>Curr Top Microbiol Immunol</i> (2000) 247:1-21	<input type="checkbox"/>
	TT	KRIEG, et al. "Rescue of B cells from apoptosis by immune stimulatory CpG DNA", <i>Springer Semin Immunopathol.</i> (2000) 22(1-2):55-61	<input type="checkbox"/>
	TU	KRIEG, et al. "Immune effects and therapeutic applications of CpG motifs in bacterial DNA", <i>Immunopharmacology</i> (2000) 48(3):303-305	<input type="checkbox"/>
	TV	KRIEG, et al. "Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA" <i>Immunol Today</i> (2000) 21(10):521-526	<input type="checkbox"/>
	TW	KRIEG, et al. "Now I know my CpGs", <i>Trends Microbiol.</i> (2001) 9(6):249-252	<input type="checkbox"/>
	TX	KRIEG, et al. "Enhancing vaccines with immune stimulatory CpG DNA", <i>Curr Opin Mol Ther.</i> (2001) 3(1):15-24	<input type="checkbox"/>
	TY	KRIEG, et al. Chapter 7: "CpG oligonucleotides as immune adjuvants", <i>Ernst Schering Research Found Workshop</i> (2001) 30:105-118	<input type="checkbox"/>
	TZ	KRIEG, et al. "Immune effects and mechanisms of action of CpG motifs", <i>Vaccine</i> (2001) 129(6):618-622	<input type="checkbox"/>
	UA	KRIEG, et al. Chapter 17: Immune stimulation by oligonucleotides", <i>Antisense Drug Tech.</i> (2001) 1394:471-515	<input type="checkbox"/>
	UB	KRIEG, et al. "CpG motifs in bacterial DNA and their immune effects", <i>Annu Rev Immunol.</i> (2002) 20:709-760	<input type="checkbox"/>
	UC	KRIEG, et al. "Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist", <i>J Immunother</i> (2004) 27(6):460-471	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/621,254
				<i>Filing Date</i>	July 14, 2003
				<i>First Named Inventor</i>	Dow, Steven W.
				<i>Art Unit</i>	1643
				<i>Examiner Name</i>	HOLLERAN, Anne L.
<i>(Use as many sheets as necessary)</i>				<i>Attorney Docket Number</i>	021819-000300US
Sheet	31	of	48		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	UD	KRIEG, et al. "P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides", <i>Oligonucleotides</i> (2003) 13(6):491-499	<input type="checkbox"/>	
	UE	KRIEG, et al. "Therapeutic potential of Toll-like receptor 9 activation", <i>Nat Rev Drug Discov</i> (2006) 5(6):471-484	<input type="checkbox"/>	
	UF	KRIEG, et al. "Antimicrobial applications of toll-like receptor 9 agonists", <i>Proc. Am Thorac Soc.</i> (2007) 4(3):289-294	<input type="checkbox"/>	
	UG	KUBY, <i>Immunology</i> , (1994) Chapter 13	<input type="checkbox"/>	
	UH	KUKOWSKA-LATALLO, et al. "Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers", <i>Proc Natl Acad Sci USA</i> (1996) 93(10):4897-4902	<input type="checkbox"/>	
	UI	KURAMOTO, et al. "In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG", <i>Microbiol Immunol</i> (1989) 33(11):929-940	<input type="checkbox"/>	
	UJ	KURAMOTO, et al. "Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction", <i>Cancer Immunol Immunother.</i> (1992) 34(5):283-288	<input type="checkbox"/>	
	UK	KURAMOTO, et al. "Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction", <i>Int J Immunopharmacol.</i> (1992) 14(5):773-782	<input type="checkbox"/>	
	UL	KURAMOTO, et al. "Oligonucleotide Sequences Required for Natural Killer Cell Activation", <i>Jpn. J. Cancer Res</i> (1992) 83:1128-1131	<input type="checkbox"/>	
	UM	LEDERMAN, et al. "Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation", <i>Antisense Nucleic Acid Drug Dev.</i> (1996) 6(4):281-289	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known Application Number 10/621,254 Filing Date July 14, 2003 First Named Inventor Dow, Steven W. Art Unit 1643 Examiner Name HOLLERAN, Anne L. Attorney Docket Number 021819-000300US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	32	of	48		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	UN	LEE, et al. "Immunostimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations", <i>Immunology</i> (1998) 94(3):285-289	<input type="checkbox"/>		
	UO	LEIBSON, et al. "Role of gamma-interferon in antibody-producing responses", <i>Nature</i> (1984) 4:309(5971):799-801	<input type="checkbox"/>		
	UP	LEONARD, et al. "Conformation of Guanine 8-Oxoadenine Base Pairs in the Crystal Structure of d(CGCGAATT(08A)GCG);", <i>Biochemistry</i> (1992) 31(36):8415-8420	<input type="checkbox"/>		
	UQ	LETSINGER, et al. "Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture", <i>Proc Natl Acad Sci USA</i> (1989) 86(17):6553-6556	<input type="checkbox"/>		
	UR	LETSINGER, et al. "Synthesis and properties of modified oligonucleotides", <i>Nucleic Acids Symp Ser.</i> (1991) 24:75-78	<input type="checkbox"/>		
	US	LI, et al. "Enhanced immune response to T-Independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes", <i>Vaccine</i> (2001) 20(1-2):148-157	<input type="checkbox"/>		
	UT	LIPFORD, et al. "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", <i>Eur J Immunol</i> (1997) 27(9):2340-2344	<input type="checkbox"/>		
	UU	LIPFORD, et al. "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines", <i>Eur J Immunol</i> (1997) 27(12):3420-3426	<input type="checkbox"/>		
	UV	LIPFORD, et al. "Bacterial DNA as immune cell activator", <i>Trends Microbiol</i> (1998) 6(12):496-500	<input type="checkbox"/>		
	UW	LITZINGER, et al. "Fate of cationic liposomes and their complex with oligonucleotide in vivo", <i>Biochim Biophys Acta</i> , (1996) 1281(2):139-149	<input type="checkbox"/>		
	UX	LIU, et al. "Recombinant interleukin-6 protects mice against experimental bacterial infection", <i>Infect Immun.</i> (1992) 60(10):4402-4406	<input type="checkbox"/>		
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/621,254
		Filing Date	July 14, 2003
		First Named Inventor	Dow, Steven W.
		Art Unit	1643
		Examiner Name	HOLLERAN, Anne L.
		Attorney Docket Number	021819-000300US
Sheet	33	of	48

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	UY	LIU, et al. "CpG ODN is an effective adjuvant in immunization with tumor antigen", <i>J Invest Med.</i> (1997) 45(7):333A	<input type="checkbox"/>
	UZ	LOKE, et al. "Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis", <i>Curr Top Microbiol Immunol.</i> (1988) 141:282-289	<input type="checkbox"/>
	VA	LONDSORF, et al. "Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity", <i>J Immunol.</i> (2003) 171(8):3941-3946	<input type="checkbox"/>
	VB	MacFARLANE, et al. "Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signaling step" <i>Immunology</i> (1997) 91(4):586-593	<input type="checkbox"/>
	VC	MacFARLANE, et al. "Antagonism of immuno-stimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds", <i>J. Immunol</i> (1998) 160(3):1122-1131	<input type="checkbox"/>
	VD	MACKELLAR, et al. "Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups", <i>Nucleic Acids Res.</i> (1992) 20(13):3411-3417	<input type="checkbox"/>
	VE	MAGNUSSON, et al. "Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus -related oligodeoxynucleotide", <i>Scand J Immunol.</i> (2001) 54(6):543-550	<input type="checkbox"/>
	VF	MAJOR, et al. "Chapter 34 Hepatitis C Virus" in <i>Fields' Virology</i> (2001) 1:1127-1161	<input type="checkbox"/>
	VG	MALLOY, et al. "Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS", <i>Eur J Immunol</i> (1995) 25(10):2834-2841	<input type="checkbox"/>
	VH	MALTESE, et al. "Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity", <i>Nucleic Acids Res</i> (1995) 23(7):1146-1151	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO			Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/621,254
			<i>Filing Date</i>	July 14, 2003
			<i>First Named Inventor</i>	Dow, Steven W.
			<i>Art Unit</i>	1643
			<i>Examiner Name</i>	HOLLERAN, Anne L.
(Use as many sheets as necessary)			<i>Attorney Docket Number</i>	021819-000300US
Sheet	34	of	48	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	VI	MANCILLA-RAMIREZ, et al. "[Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by <i>Klebsiella pneumoniae</i>]" <i>Gac Med Mex</i> (1995) 131(1):14-22	<input type="checkbox"/>	
	VJ	MANEGOLD, et al. "Addition of PF-3512676 (CpG 7909) to a taxane/platinum regimen for first line treatment of unresectable non-small cell lung cancer (NSCLC) improves objective response-Phase II clinical trial", <i>Pfizer Poster</i> (2005) Abstract 1131	<input type="checkbox"/>	
	VK	MARTIN-OROZCO, et al. "Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences", <i>Int Immunol</i> (1999) 11(7):1111-1118	<input type="checkbox"/>	
	VL	MASTRANGELO, et al. <i>Seminars in Oncology</i> (1996) 23(1):4-21	<input type="checkbox"/>	
	VM	MATSON, S., et al. "Nonspecific suppression of [3H] thymidine incorporation by "control" oligonucleotides", <i>Antisense Res Dev</i> (1992) 2(4):325-330	<input type="checkbox"/>	
	VN	MATSUKURA, et al. "Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (arts/trs) in chronically infected cells", <i>Proc Natl Acad Sci USA</i> (1989) 86(11):4244-4248	<input type="checkbox"/>	
	VO	McCLUSKIE, et al. "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice", <i>J Immunol.</i> (1998) 161(9):4463-4466	<input type="checkbox"/>	
	VP	McCLUSKIE, et al. "CpG DNA as mucosal adjuvant" <i>Vaccine</i> (2000) 18:231-237	<input type="checkbox"/>	
	VQ	McCLUSKIE, et al. "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants", <i>Vaccine</i> (2001) 19(4-5):413-422	<input type="checkbox"/>	
	VR	McCLUSKIE, et al. "CpG DNA is an effective oral adjuvant to protein antigens in mice", <i>Vaccine</i> (2001) 19(7-8):950-957	<input type="checkbox"/>	
	VS	McCLUSKIE, et al. "Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates", <i>Mol Med.</i> (1999) 5(5):287-300	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
Art Unit		1643			
Examiner Name		HOLLERAN, Anne L.			
Sheet	35	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	VT	McCLUSKIE, et al. "The use of CpG DNA as a mucosal vaccine adjuvant", <i>Curr Opin Investig Drugs</i> (2001) 2(1):35-39	<input type="checkbox"/>	
	VU	McCLUSKIE Vaccine (2001) 19:3759-3768	<input type="checkbox"/>	
	VV	McCLUSKIE, et al. "Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of <i>Escherichia coli</i> as adjuvants", <i>Vaccine</i> (2001) 27:352-354	<input type="checkbox"/>	
	VW	McCLUSKIE, et al. "Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution", <i>Mol Med</i> (2000) 6(10):867-877	<input type="checkbox"/>	
	VX	McCLUSKIE, et al. "The role of CpG in DNA vaccines", <i>Springer Semin Immunopathol</i> (2000) 22(1-2):125-132	<input type="checkbox"/>	
	VY	McGHEE, et al. "The mucosal immune system: from fundamental concepts to vaccine development", <i>Vaccine</i> (1992) 10(2):75-88	<input type="checkbox"/>	
	VZ	McHUTCHISON, et al. "Early viral response to CpG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response", <i>41st Annual Meeting of European Association for the Study of the Liver (EASL)</i> (2006) April 26-30, Vienna, Austria, submitted Abstract	<input type="checkbox"/>	
	WA	McHUTCHISON, et al. "Final results of a multi-center phase 1B, randomized, placebo-controlled, dose escalation trial of CpG 10101 in patients with chronic hepatitis C virus", <i>41st Annual Meeting of European Association for the Study of the Liver (EASL)</i> (2006) April 30, Vienna, Austria, presented Abstract #111	<input type="checkbox"/>	
	WB	McHUTCHISON, et al. "Early clinical results with CpG 10101, a new investigational antiviral TLT9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus", <i>12th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD)</i> (2006) July 3, Paris, France; presented Abstract #O105	<input type="checkbox"/>	
	WC	McIntyre, K., et al. "A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation", <i>Antisense Res Dev</i> (1993) 3(4):309-322	<input type="checkbox"/>	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			<i>Application Number</i>	10/621,254	
			<i>Filing Date</i>	July 14, 2003	
			<i>First Named Inventor</i>	Dow, Steven W.	
			<i>Art Unit</i>	1643	
			<i>Examiner Name</i>	HOLLERAN, Anne L.	
			<i>Attorney Docket Number</i>	021819-000300US	
Sheet	36	of	48		

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	WD	MESSINA, J.P., et al. "Stimulation of <i>in vitro</i> murine lymphocyte proliferation by bacterial DNA", <i>J. Immunol.</i> (1991) 147(6):1759-1764	<input type="checkbox"/>	
	WE	MESSINA, J.P., et al. "The influence of DNA structure on the <i>in vitro</i> stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens", <i>Cell Immunol.</i> (1993) 147(1):148-157	<input type="checkbox"/>	
	WF	MICONNET, et al. "CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide", <i>J Immunol</i> (2002) 168(3):1212-1218	<input type="checkbox"/>	
	WG	MILAS, et al. "CpG oligodeoxynucleotide enhances tumor response to radiation", <i>Cancer Res.</i> (2004) 64(15):5074-5077	<input type="checkbox"/>	
	WH	MOJCIC, C.F., et al. "Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects <i>in vivo</i> in a sequence-specific manner", <i>Clinical Immunology and Immunopathology</i> (1993) 67:130-136	<input type="checkbox"/>	
	WI	MOTTRAM, et al. "A novel CDC2-related protein kinase from <i>leishmania mexicana</i> , LmmCRK1, is post-translationally regulated during the life cycle", <i>J. Biol.Chem.</i> (1993) 268:28 21044-21052	<input type="checkbox"/>	
	WJ	MUHLHAUSER, et al. "VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis <i>in vivo</i> ", <i>Circ Res.</i> (1995) 77(6):1077-1086	<input type="checkbox"/>	
	WK	MUI, et al. "Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles", <i>J Pharmacol Exp Ther.</i> (2001) 298(3):1185-1192	<input type="checkbox"/>	
	WL	MUTWIRI, et al. "Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides", <i>J. Control Release</i> (2004) 97(1):1-17	<input type="checkbox"/>	
	WM	New England Biolabs 1993/94 Catalog, pp. 87-89 and 95 (1993)	<input type="checkbox"/>	
	WN	NIELSEN, et al. "Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone", <i>Bioconjug Chem.</i> (1994) 5(1):3-7	<input type="checkbox"/>	
Examiner Signature			Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO			Complete if Known Application Number 10/621,254 Filing Date July 14, 2003 First Named Inventor Dow, Steven W. Art Unit 1643 Examiner Name HOLLERAN, Anne L. Attorney Docket Number 021819-000300US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				
Sheet	37	of	48	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	WO	NORMAN, et al. "Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation", <i>Gene Ther.</i> (2000) 7:1425-1430	<input type="checkbox"/>	
	WP	NYCE, J., et al. "DNA antisense therapy for asthma in an animal model", <i>Nature</i> (1997) 385:721-725	<input type="checkbox"/>	
	WQ	OCHIAI, et al. "Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of biological response modifiers in gastric cancer patients", <i>Int J Immunotherapy</i> (1986) 11(4):259-265	<input type="checkbox"/>	
	WR	Official Action for US Serial No. 08/386,063, filed Feb. 7, 1995, mailed March 12, 1999	<input type="checkbox"/>	
	WS	OKADA, et al. "Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms", <i>Int J Cancer</i> (1998) 78(2):196-201	<input type="checkbox"/>	
	WT	PAL, et al. "Immunization with Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge", <i>Infect Immun</i> (2002) 70(9):4812-4817	<input type="checkbox"/>	
	WU	PAVLICK, et al. "Novel therapeutic agents under investigation for malignant melanoma", <i>Expert Opin Investig Drugs</i> (2003) 12(9):1545-1548	<input type="checkbox"/>	
	WV	PAYETTE, et al. "History of vaccines and positioning of current trends", <i>Curr Drug Targets Infect Disord.</i> (2001) 1(3):241-247	<input type="checkbox"/>	
	WW	PERLAKY, et al. "Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression", <i>Anticancer Drug Des.</i> (1993) 8(1):3-14	<input type="checkbox"/>	
	WX	PISETSKY, D.S., et al. "Stimulation of <i>in vitro</i> proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", <i>Molecular Biology Reports</i> (1993) 18(3):217-221	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/621,254
				<i>Filing Date</i>	July 14, 2003
				<i>First Named Inventor</i>	Dow, Steven W.
				<i>Art Unit</i>	1643
				<i>Examiner Name</i>	HOLLERAN, Anne L.
(Use as many sheets as necessary)				<i>Attorney Docket Number</i>	021819-000300US
Sheet	38	of	48		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	WY	PISETSKY, D.S., et al. "Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus", <i>Life Science</i> (1994) 54(2):101-107	<input type="checkbox"/>		
	WZ	PISETSKY, D.S., et al. "Immunological properties of bacterial DNA", <i>Ann N Y Acad Sci</i> (1995) 772:152-163	<input type="checkbox"/>		
	XA	PISETSKY, D.S., et al. "Immunologic consequences of nucleic acid therapy", <i>Antisense Res Dev</i> (1995) 5(3):219-225	<input type="checkbox"/>		
	XB	PISETSKY, et al. "The influence of base sequence on the immunological properties of defined oligonucleotides", <i>Immunopharmacology</i> (1998) 40(3):199-208	<input type="checkbox"/>		
	XC	PISETSKY, et al. "The influence of base sequence on the immunostimulatory properties of DNA", <i>Immunol Res</i> (1999) 19(1):35-46	<input type="checkbox"/>		
	XD	PISETSKY, et al. "Influence of backbone chemistry on immune activation by synthetic oligonucleotides", <i>Biochem Pharmacol</i> (1999) 58(12):1981-1988	<input type="checkbox"/>		
	XE	POLANCZYK, et al. "Immunostimulatory effects of DNA and CpG motifs", <i>Cent Eur J of Immunol</i> (2000) 25(3):160-166	<input type="checkbox"/>		
	XF	Promega Catalog 1993/94, P. 90 (1993)	<input type="checkbox"/>		
	XG	QUDDUS, J., et al. "Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice", <i>J Clin Invest</i> (1993) 92(1):38-53	<input type="checkbox"/>		
	XH	RAGHAVAN, et al. "Orally administered CpG oligodeoxynucleotide induces production of CXK and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of <i>Helicobacter pylori</i> infection", <i>Infect Immun</i> (2003) 71(12):7014-7022	<input type="checkbox"/>		
	XI	RANKIN, et al. "CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved", <i>Antisense Nucleic Acid Drug Dev</i> (2001) 11(5):333-340	<input type="checkbox"/>		
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
		Art Unit		1643	
		Examiner Name		HOLLERAN, Anne L.	
		Attorney Docket Number		021819-000300US	
Sheet	39	of	48		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	XJ	RATAJCZAK, et al. "In vivo treatment of human leukemia in a scid mouse model with c-myc antisense oligodeoxynucleotides", <i>Proc Natl Acad Sci USA</i> (1992) 89(24):11823-11827	<input type="checkbox"/>	
	XK	RAZ, et al. <i>Proc Natl Acad Sci USA</i> (1994) 91:9519-9523	<input type="checkbox"/>	
	XL	RAZ, <i>Proc Natl Acad Sci USA</i> (1996) 93:5141-5145	<input type="checkbox"/>	
	XM	RAZ, et al. "Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity" <i>ACR Post Session C: Cytokines and Inflammatory Mediators</i> (1996), Abstract 615	<input type="checkbox"/>	
	XN	REDDY, et al. "Design of synthetic immunostimulatory motifs as agonists of Toll-like receptor 9: Use of N3-methyl-dC and N1-methyl-dG", 231 st ACS National Meeting, Atlanta, GA, US. March 26-30, 2006 Meeting Abstract	<input type="checkbox"/>	
	XO	REITZ, et al. "Small-molecule immunostimulants. Synthesis and activity of 7,8-disubstituted guanosines and structurally related compounds", <i>J Med Chem.</i> (1994) 37(21):3561-3578	<input type="checkbox"/>	
	XP	Ren Jun, et al. HCAPLUSs Database, AN: 198874, Abstract. 1994	<input type="checkbox"/>	
	XQ	REVAZ, et al. "The importance of mucosal immunity in defense against epithelial cancers", <i>Curr Opin Immunol</i> (2005) 17(2):175-179	<input type="checkbox"/>	
	XR	ROBERTSON, et al. "Crohn's trial shows the pros of antisense", <i>Nat Biotechnol</i> (1997) 15(3):209	<input type="checkbox"/>	
	XS	RODGERS, et al. "Effects of acute administration of O,S,S-trimethyl phosphorodithioate on the generation of cellular and humoral immune responses following in vitro stimulation", <i>Toxicology</i> (1988) 51(2-3):241-253	<input type="checkbox"/>	
	XT	ROJANASAKUL, Y. "Antisense oligonucleotide therapeutics: drug delivery and targeting", <i>Advanced Drug Delivery Reviews</i> (1996) 18:115-131	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
				Art Unit	
				1643	
				Examiner Name	
				HOLLERAN, Anne L.	
Sheet		40	of	48	Attorney Docket Number
					021819-000300US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	XU	ROTHENFUSSE, et al. "Recent advances in immunostimulatory CpG oligonucleotides", <i>Curr Opin Mol Ther.</i> (2003) 5(2):98-106	<input type="checkbox"/>		
	XV	RUDGINSKY, et al. "Antitumor activity of cationic lipid complexed with immunostimulatory DNA" <i>Mol Ther.</i> (2001) 4(4):347-355	<input type="checkbox"/>		
	XW	RYNKIEWICZ, et al. "Marked enhancement of antibody response to anthrax vaccine adsorbed with CPT 7909 in healthy volunteers", <i>45th Intersci. Conf. Antimicrob. Agents Chemother.</i> (2005 Sept. 21-24); New Orleans, Louisiana. Meeting Poster	<input type="checkbox"/>		
	XX	SAJIC, et al. "Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge", <i>J Med Virol</i> (2003) 71(4):561-568	<input type="checkbox"/>		
	XY	SANDS, et al. "Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate", <i>Mol Pharmacol.</i> (1994) 45(5):932-943	<input type="checkbox"/>		
	XZ	SATO, et al. "The study of mechanisms in CpG oligodeoxynucleotides-induced aggravation in murine allergic contact dermatitis to 2,4-dinitrofluorobenzene", <i>Fukushima Igaku Zasshi</i> (2002) 52(3):237-250. Abstract	<input type="checkbox"/>		
	YA	SCHMIDT, et al. "Cytokine and Ig-production by CG-containing sequences with phosphodiester backbone and dumbbell-shape", <i>Allergy</i> (2006) 61(1):56-63	<input type="checkbox"/>		
	YB	SCHNELL, et al. "Identification and characterization of a <i>Saccharomyces cerevisiae</i> gene (PAR1) conferring resistance to iron chelators", <i>Eur. J. Biochem.</i> 200:487-493	<input type="checkbox"/>		
	YC	SCHWARTZ, D.A. et al. "CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract", <i>J Clin Invest</i> (1997) 100(1):68-73	<input type="checkbox"/>		
	YD	SCHWARTZ, et al. "Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway", <i>J Immunol.</i> (1999) 63(1):224-231	<input type="checkbox"/>		
	YE	SEDEGAH, et al. "Interleukin 12 induction of interferon gamma-dependent protection against malaria", <i>Proc natl Acad Sci USA</i> (1994) 91(22):10700-2	<input type="checkbox"/>		
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
				Examiner Name	HOLLERAN, Anne L.
Sheet	41	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	YF	SEMPLE, et al. "Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid", <i>J Pharmacol Exp Ther</i> (2005) 312(3):1020-1026 (Epub 2004 Nov. 3)	<input type="checkbox"/>		
	YG	SESTER, et al. "Phosphorothioate backbone modification modulates macrophage activation by CpG DNA", <i>J Immunol.</i> (2000) 165(8):4165-4173	<input type="checkbox"/>		
	YH	SHCHEPINOV, et al. "Oligonucleotide dendrimers: From poly-labelled DNA probes to stable nano-structures. Glen Research Glen Report located at < http://www.glenresearch.com/glenreports/GR12-11.html >, visited on March 3, 2006, 7 pages	<input type="checkbox"/>		
	YI	SHCHEPINOV, et al. "Oligonucleotide dendrimers: stable nano-structures", <i>Nucleic Acids Res.</i> (1999) 27(15):3035-3041	<input type="checkbox"/>		
	YJ	SHIRAKAWA T., et al. "The inverse association between tuberculin responses and atopic disorder", <i>Science</i> (1997) 275(5296):77-79	<input type="checkbox"/>		
	YK	SIDMAN, et al. "Gamma-interferon is one of several direct B cell-maturing lymphokines", <i>Nature</i> (1984) 309(5971):801-804	<input type="checkbox"/>		
	YL	SINGH, et al. "Cationic microparticles are an effective delivery system for stimulatory CpG DNA", <i>Pharm Res.</i> (2001) 18(10):1476-1479	<input type="checkbox"/>		
	YM	SJOLANDER, et al. "Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins", <i>Scand J Immunol.</i> (1996) 43(2):164-172	<input type="checkbox"/>		
	YN	SONEHARA, et al. "Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon", <i>J Interferon Cytokine Res.</i> (1996) 16(10):799-803	<input type="checkbox"/>		
	YO	SPARWASSER, et al. "Bacterial DNA causes septic shock", <i>Nature</i> (1997) 386(6623):336-337	<input type="checkbox"/>		
	YP	SPARWASSER, et al. "Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis", <i>J Immunol</i> (1999) 162(4):2368-2374	<input type="checkbox"/>		
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/621,254
				<i>Filing Date</i>	July 14, 2003
				<i>First Named Inventor</i>	Dow, Steven W.
				<i>Art Unit</i>	1643
				<i>Examiner Name</i>	HOLLERAN, Anne L.
<i>(Use as many sheets as necessary)</i>				<i>Attorney Docket Number</i>	021819-000300US
Sheet	42	of	48		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	YQ	SPARWASSER, et al. "Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock", <i>Eur J Immunol.</i> (1997) 27(7):1671-1679			<input type="checkbox"/>
	YR	STEIN, et al. "Physicochemical properties of phosphorothioate oligodeoxynucleotides", <i>Nucleic Acids Res.</i> (1988) 16(8):3209-3221			<input type="checkbox"/>
	YS	STEIN, et al. "Oligodeoxynucleotides as inhibitors of gene expression: a review", <i>Cancer Research</i> (1988) 48:2659-2668			<input type="checkbox"/>
	YT	STEIN, C.A., et al. "Antisense oligonucleotides as therapeutic agents - is the bullet really magical", <i>Science</i> (1993) 261:1004-1012			<input type="checkbox"/>
	YU	STEIN, et al. "Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides", <i>Antisense Res Dev.</i> (1994) 4(2):67-69			<input type="checkbox"/>
	YV	STEIN, et al. "Non-antisense effects of oligodeoxynucleotides", <i>Antisense Technology</i> (1997) ch 11:241-264			<input type="checkbox"/>
	YW	STIRCHAK, et al. "Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages", <i>Nucleic Acids Res.</i> (1989) 17(15):6129-6141			<input type="checkbox"/>
	YX	STULL, et al. "Antigene, Ribozyme, and Aptamer Nucleic Acid Drugs: Progress and Prospects", <i>Pharmaceutical Res.</i> (1995) 12(4):465-483			<input type="checkbox"/>
	YY	STUNZ, et al. "Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells", <i>Eur J Immunology</i> (2002) 32(5):1212-1222			<input type="checkbox"/>
	YZ	SUBRAMANIAN, et al. "Theoretical Considerations on the 'Spine of Hydration' in the Minor Groove of d(CGCGAATTCGCG) d(CGCTTAAGCGC): Monte Carlo Computer Simulation", <i>Proc Natl Acad Sci USA</i> (1988) 85:1836-1840			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/621,254
				<i>Filing Date</i>	July 14, 2003
				<i>First Named Inventor</i>	Dow, Steven W.
				<i>Art Unit</i>	1643
				<i>Examiner Name</i>	HOLLERAN, Anne L.
				<i>Attorney Docket Number</i>	021819-000300US
Sheet	43	of	48		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	ZA	SUN, et al. "Type I interferon-mediated stimulation of T cells by CpG DNA", <i>J Exp Med.</i> (1998) 188(12):2335-2342	<input type="checkbox"/>	
	ZB	SUN, et al. "Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons", <i>Springer Semin Immunopathol.</i> (2000) 22(1-2):77-84	<input type="checkbox"/>	
	ZC	SUZUKI, et al. "Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity", <i>Cancer Res</i> (2004) 64(23):8754-8760	<input type="checkbox"/>	
	ZD	SUZUKI, et al. "Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity", <i>Cancer Res</i> (2004) 64(23):8754-8760	<input type="checkbox"/>	
	ZE	TACKET, et al. "Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device", <i>Vaccine</i> (1999) 17(22):2826-2829	<input type="checkbox"/>	
	ZF	TAKATSUKI, et al. "Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment", <i>Cancer Res</i> (1990) 50(10):2885-2890	<input type="checkbox"/>	
	ZG	TAM, et al. "Liposomal encapsulation enhances the activity of immunostimulatory oligonucleotides", <i>Future Lipidology</i> (2006) 1(1):35-46	<input type="checkbox"/>	
	ZH	TANAKA, T., et al. "An antisense oligonucleotide complementary to a sequence in Iy2b increases y2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion", <i>J. Exp. Med.</i> (1992) 175:597-607	<input type="checkbox"/>	
	ZI	TARKOY, et al. "Nucleic-Acid Analogues with Constraint Conformational Flexibility in the Sugar-Phosphate Backbone ('Bicyclo-DNA'). Part I. Preparation of (3S,5R)-2'-Deoxy-3,5'-ethano- α -D-ribose nucleosides ('Bicyclonucleosides')", <i>Helv Chim Acta</i> (1993) 76(1):481-510	<input type="checkbox"/>	
	ZJ	THREADGILL, et al. "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", <i>Vaccine</i> (1998) 16(1):76-82	<input type="checkbox"/>	
	ZK	TOKUNAGA, et al. "A Synthetic Single-Stranded DNA, Poly (dG, dC), Induces Interferon α/β and - γ , Augments Natural Killer Activity and Suppresses Tumor Growth", <i>Jpn. J. Cancer Res.</i> (1988) 79:682-686	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/621,254
		<i>Filing Date</i>	July 14, 2003
		<i>First Named Inventor</i>	Dow, Steven W.
		<i>Art Unit</i>	1643
		<i>Examiner Name</i>	HOLLERAN, Anne L.
		<i>Attorney Docket Number</i>	021819-000300US
Sheet	44	of	48

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	ZL	TOKUNAGA, et al. "Synthetic Oligonucleotides with Particular Base Sequence from the cDNA Encoding Proteins of <i>Mycobacterium bovis</i> BCG Induce Interferons and Activate Natural Killer Cells", <i>Microbiol. Immunol.</i> (1992) 36(1):55-66	<input type="checkbox"/>
	ZM	TOKUNAGA, et al. "Response of the organism to DNA - With a focus on immunostimulatory DNA", <i>Kansen-Ensho-Meneki</i> (2001) 31(3):1-12	<input type="checkbox"/>
	ZN	UHLMANN, et al. "Antisense Oligonucleotides: A New Therapeutic Principle", <i>Chemical Reviews</i> (1990) 90:543-584	<input type="checkbox"/>
	ZO	UHLMANN, et al. "Recent advances in the development of immunostimulatory oligonucleotides", <i>Curr Opin Drug Discov Devel.</i> (2003) 6(2):204-217	<input type="checkbox"/>
	ZP	VANENDRIESSCHE, et al. "Acyclic oligonucleotides: possibilities and limitations", <i>Tetrahedron</i> (1993) 49(33):7223-7238	<input type="checkbox"/>
	ZQ	VERTHELYI, et al. "Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs", <i>J Immunol.</i> (2001) 166(4):2372-2377	<input type="checkbox"/>
	ZR	VERTHELYI, et al. "Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates", <i>Clin Immunol.</i> (2003) 109(1):64-71	<input type="checkbox"/>
	ZS	VICARI, et al. "Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody", <i>J Exp Med.</i> (2002) 196(4):541-549	<input type="checkbox"/>
	ZT	VLASSOV, et al. "In Vivo pharmacokinetics of oligonucleotides following administration by different routes", CRC Press, Inc. Chapter 5 (1995) pp. 71-83	<input type="checkbox"/>
	ZU	VOLLMER, et al. "Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes", <i>Antisense Nucleic Acid Drug Dev.</i> (2002) 12(3):165-175	<input type="checkbox"/>
	ZV	VOLLMER, et al. "Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities", <i>Eur J Immunol</i> (2004) 34(1):251-262	<input type="checkbox"/>
Examiner Signature			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/621,254
				Filing Date	July 14, 2003
				First Named Inventor	Dow, Steven W.
				Art Unit	1643
				Examiner Name	HOLLERAN, Anne L.
Sheet	45	of	48	Attorney Docket Number	021819-000300US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	ZW	VOLLMER, et al. "Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA)", <i>Oligonucleotides</i> (2004) 14(1):23-31	<input type="checkbox"/>	
	ZX	WAAG, et al. "Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice", <i>Ann N Y Acad Sci</i> (1990) 590:203-214	<input type="checkbox"/>	
	ZY	WAGNER, "Gene inhibition using antisense oligodeoxynucleotides", <i>Nature</i> (1994) 372:L333-335	<input type="checkbox"/>	
	ZZ	WAGNER, "Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity", <i>Curr Opin Microbiol.</i> (2002) 5(1):62-69	<input type="checkbox"/>	
	AAA	WAGNER, et al. "CpG motifs are efficient adjuvants for genetic vaccines to induce antigen-specific protective anti-tumor T cell responses", 2000:203:429. Abstract R46	<input type="checkbox"/>	
	AAB	WALLACE, et al. "Oligonucleotide probes for the screening of recombinant DNA libraries", <i>Methods in Enzymology</i> (1987) 152:432-442	<input type="checkbox"/>	
	AAC	WANG, et al. "CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma", <i>World J Gastroenterol</i> (2005) 11(8):1220-1224	<input type="checkbox"/>	
	AAD	WEERANTHA, et al. "Reduction of Antigen Expression from DNA Vaccines by coadministered Oligodeoxynucleotides", <i>Antisense and Nucleic Acid Drug Development</i> (1998) 8:351-356	<input type="checkbox"/>	
	AAE	WEERATNA, et al. "CpG ODN can redirect the Th bias of established Th2 immune responses in adult and young mice", <i>FEMS Immunol Med Microbiol</i> (2001) 32(1):65-71	<input type="checkbox"/>	
	AAF	WEERATNA, et al. "CpG DNA induces stronger immune responses with less toxicity than other adjuvants", <i>Vaccine</i> (2000) 18(17):1755-1762	<input type="checkbox"/>	
	AAG	WEINER, et al. "Immunostimulatory CpG oligodeoxynucleotide is effective as an adjuvant in inducing production of anti-idiotypic antibody and is synergistic with GM-CSF", <i>Blood</i> (1996) 88(10):Suppl. 1 pt. 1. Abstract #348	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/621,254	
				Filing Date	
				July 14, 2003	
				First Named Inventor	
		Dow, Steven W.			
				Art Unit	
				1643	
				Examiner Name	
				HOLLERAN, Anne L.	
				Attorney Docket Number	
				021819-000300US	
Sheet	46	of	48		

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AAH	WEINER, et al. "The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides", <i>J Leukoc Biol.</i> (2000) 68(4):455-463	<input type="checkbox"/>
	AAI	WEISS, R. "Upping the Antisense Ante: Scientists bet on profits from reverse genetics", <i>Science</i> (1991) 139:108-109	<input type="checkbox"/>
	AAJ	WERNETTE, et al. "CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation", <i>Vet Immunol Immunopathol.</i> (2002) 84(3-4):223-236	<input type="checkbox"/>
	AAK	WHALEN, R., "DNA vaccines for emerging infection diseases: What If?", <i>Emerging Infectious Disease</i> (1996) 2(3):168-175	<input type="checkbox"/>
	AAL	WHITESELL, et al. "Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: Implications for therapeutic application within the central nervous system", <i>Proc Natl Acad Sci USA</i> (1993) 90(10):4665-4669	<input type="checkbox"/>
	AAM	WHITMORE, et al. "LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth", <i>Gene Ther.</i> (1999) 6:1867-1875	<input type="checkbox"/>
	AAN	WHITMORE, et al. "Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses", <i>Canc Immun Immunother.</i> (2001) 50:503-514	<input type="checkbox"/>
	AAO	WOOLDRIDGE, et al. "Select unmethylated CpG oligodeoxynucleotide improve antibody dependent cellular cytotoxicity in vitro and in vivo", <i>Proc Am Assoc Cancer Res</i> (1996) 37(3253):477	<input type="checkbox"/>
	AAP	WOOLDRIDGE, et al. "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma", <i>Blood</i> (1997) 89(8):2994-2998	<input type="checkbox"/>
	AAQ	WU, G.Y., et al. "Receptor-mediated gene delivery and expression in vivo", <i>J. Biological Chemistry</i> (1988) 263:14621-14624	<input type="checkbox"/>
	AAR	WU-PONG, S. "Oligonucleotides: Opportunities for Drug Therapy and Research", <i>Pharmaceutical Technology</i> (1994) 18:102-114	<input type="checkbox"/>
Examiner Signature			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/621,254
		<i>Filing Date</i>	July 14, 2003
		<i>First Named Inventor</i>	Dow, Steven W.
		<i>Art Unit</i>	1643
		<i>Examiner Name</i>	HOLLERAN, Anne L.
		<i>Attorney Docket Number</i>	021819-000300US
Sheet	47	of	48

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AAS		YAMAMOTO, S., et al. "In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and gamma with deoxyribonucleic acid fraction from <i>Mycobacterium bovis</i> BCG". <i>Jpn J Cancer Res</i> (1988) 79:866-873	<input type="checkbox"/>
AAT		YAMAMOTO, S., et al. "Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity". <i>The Journal of Immunology</i> (1992) 148:4072-4076	<input type="checkbox"/>
AAU		YAMAMOTO, S., et al. "DNA from Bacteria, but Not from Vertebrates, Induces Interferons, Activates Natural Killer Cells and Inhibits Tumor Growth". <i>Microbiol. Immunol.</i> (1992) 36(9):993-997	<input type="checkbox"/>
AAV		YAMAMOTO, S., et al. "Mode of Action of Oligonucleotide Fraction Extracted From <i>Mycobacterium bovis</i> BCG". <i>Kekkaku</i> (1994) 69(9):29-32	<input type="checkbox"/>
AAW		YAMAMOTO, T., et al. "Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length". <i>Antisense Research and Development</i> (1994) 4:119-123	<input type="checkbox"/>
AAX		YAMAMOTO, T., et al. "Synthetic Oligonucleotides with Certain Palindromes Stimulate Interferon Production of Human Peripheral Blood Lymphocytes in vitro". <i>Jpn J. Cancer Res</i> (1994) 85:775-779.	<input type="checkbox"/>
AAV		YAMAMOTO, T., et al. "Cytokine production inducing action of oligo DNA". <i>Rinsho Meneki</i> (1997) 29(2):1178-1184	<input type="checkbox"/>
AAZ		Yi, et al. "Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway". <i>J Immunol</i> (1996) 157(12):5394-5402	<input type="checkbox"/>
BBA		Yi, et al. "IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides". <i>J Immunol.</i> (1996) 154(2):558-564	<input type="checkbox"/>
BBB		Yi, et al. "Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA". <i>J Immunol.</i> (1998) 161(9):4493-4497	<input type="checkbox"/>
BBC		Yi, et al. "CpG oligodeoxynucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry". <i>J Immunol.</i> (1998) 160(12):5898-5906	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known Application Number 10/621,254 Filing Date July 14, 2003 First Named Inventor Dow, Steven W. Art Unit 1643 Examiner Name HOLLERAN, Anne L. Attorney Docket Number 021819-000300US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	48	of	48		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	BBD	YU, et al. "Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity", <i>Bloorg Med Chem Lett</i> (2000) 10(23):2585-2588	<input type="checkbox"/>	
	BBE	YU, et al. "Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases", <i>Bloorg Med Chem Lett.</i> (2001) 11(17):2263-2267	<input type="checkbox"/>	
	BBF	ZHAO, Q., et al. "Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors", <i>Blood</i> (1994) 84(11):3660-3666	<input type="checkbox"/>	
	BBG	ZHAO, et al. "Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs", <i>Biochem Pharmacol</i> (1996) 52(10):1537-1544	<input type="checkbox"/>	
	BBH	ZHAO, et al. "Effect of different chemically modified oligodeoxynucleotides on immune stimulation", <i>Biochem Pharmacol</i> (1996) 51(2):173-182	<input type="checkbox"/>	
	BBI	ZHAO, et al. "Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice", <i>Antisense Nucleic Acid Drug Dev.</i> (1997) 7(5):495-502	<input type="checkbox"/>	
	BBJ	ZHAO, et al. "Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity", <i>Bloorg Med Chem Lett</i> (1999) 9(24):3453-3458	<input type="checkbox"/>	
	BBK	ZHAO, et al. "Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside", <i>Bloorg Med Chem Lett.</i> (2000) 10(10):1051-1054. Abstract Only	<input type="checkbox"/>	
	BBL	ZHU, et al. "Modulation of ovalbumin-induced Th2 responses by second generation immunomodulatory oligonucleotides in mice", <i>Int Immunopharmacol</i> (2004) 4(7):851-862	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.